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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 21, Revision 4 
(FGE.21Rev4): 
Thiazoles, thiophenes, thiazoline and thienyl derivatives from chemical 
groups 29 and 301 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and 
Processing Aids (CEF)2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to evaluate 59 flavouring substances in the Flavouring Group Evaluation 21, Revision 
4, using the Procedure in Commission Regulation (EC) No 1565/2000. This revision is made due to the inclusion 
of the assessment of new toxicity data on one supporting substance 5,6-dihydro-2,4,6-tris(2-methylpropyl)-4H-
1,3,5-dithiazine [FL-no: 15.113], which is considered to be structurally related to the candidate substances 2-
butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-dithiazine [FL-no: 15.042], dihydro-2,4,6-triethyl-1,3,5(4H)-
dithiazine [FL-no: 15.054], 2,4-dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine [FL-no: 15.055], 4,6-dimethyl-2-
(1-methylethyl)dihydro-1,3,5-dithiazine [FL-no: 15.057], 2-isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine [FL-
no: 15.079] and ethyl thialdine [FL-no: 15.135]. Furthermore, new in vitro genotoxicity studies have become 
available on the supporting substance 2-acetyl-2-thiazoline [FL-no: 15.010], which is considered to be 
structurally related to and a supportive substance for 2-methyl-2-thiazoline [FL-no: 15.086]. Eighteen of the 
original 59 candidate substances [FL-no: 15.037, 15.042, 15.043, 15.064, 15.070, 15.072, 15.077, 15.088, 
15.090, 15.091, 15.092, 15.094, 15.099, 15.106, 15.107, 15.114, 15.129 and 15.133], for which additional data 
were requested, are no longer supported by Industry for use as flavouring substances in Europe and will 
therefore not be considered any further. Therefore, FGE.21Rev4 will only deal with 41 candidate substances. 
Two of the substances, 3-thiazolines, 2,4-dimethyl-3-thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-
no: 15.119], were considered to have genotoxic potential. The remaining 39 substances were evaluated through a 
stepwise approach (the Procedure) that integrates information on structure-activity relationships, intake from 
current uses, toxicological threshold of concern, and available data on metabolism and toxicity. The Panel 
concluded that 32 flavouring substances [FL-no: 15.038, 15.039, 15.044, 15.050, 15.051, 15.052, 15.054, 
15.055, 15.057, 15.058, 15.061, 15.062, 15.063, 15.067, 15.068, 15.069, 15.071, 15.078, 15.079, 15.080, 15.082, 
                                                     
1  On request from the European Commission, Question No EFSA-Q-2013-00181, EFSA-Q-2013-00224, EFSA-Q-2013-
00225, EFSA-Q-2013-00226, EFSA-Q-2013-00227, EFSA-Q-2013-00228, adopted on 24 October 2013. 
2  Panel members: Ulla Beckman Sundh, Mona-Lise Binderup, Claudia Bolognesi, Leon Brimer, Laurence Castle, 
Alessandro Di Domenico, Karl-Heinz Engel, Roland Franz, Nathalie Gontard, Rainer Gürtler, Trine Husøy, Klaus-Dieter 
Jany, Martine Kolf-Clauw, Wim Mennes, Maria Rosaria Milana, Iona Pratt, Kettil Svensson, Maria de Fatima Tavares 
Poças, Fidel Toldra and Detlef Wölfle. Correspondence: cef@efsa.europa.eu   
3  Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings: Ulla Beckman Sundh, 
Leon Brimer, Angelo Carere, Karl-Heinz Engel, Henrik Frandsen, Rainer Gürtler, Trine Husøy, John Christian Larsen, 
Wim Mennes, Gerard Mulder and Harriet Wallin for the preparatory work on this scientific opinion and the hearing 
experts: Vibe Beltoft, Pia Lund and Karin Nørby and EFSA staff: Annamaria Rossi and Kim Rygaard Nielsen for the 
support provided to this scientific opinion. 
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15.084, 15.085, 15.086, 15.087, 15.089, 15.098, 15.108, 15.115, 15.116, 15.118 and 15.135] do not give rise to 
safety concerns at their levels of dietary intake, estimated on the basis of the MSDI approach. For the remaining 
seven candidate substances [FL-no: 15.040, 15.045, 15.074, 15.076, 15.093, 15.096 and 15.097] evaluated 
through the Procedure, no appropriate NOAEL was available and additional data are required. Besides the safety 
assessment of these flavouring substances, the specifications for the materials of commerce have also been 
considered. Adequate specifications including complete purity criteria and identity for the materials of 
commerce have been provided for all 41 candidate substances. 
© European Food Safety Authority, 2013 
KEY WORDS 
flavourings, safety, thiophene derivatives, thiazole derivatives, thiazoline derivatives, dithiazine 
derivatives, FGE.21 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to deliver a scientific opinion to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate 41 flavouring substances in the 
Flavouring Group Evaluation (FGE) 21, Revision 4 (FGE.21Rev4), using the Procedure as referred to 
in the Commission Regulation (EC) No 1565/2000. These 41 flavouring substances belong to 
chemical group 29 and 30, Annex I of the Commission Regulation (EC) No 1565/2000.  
The present revision of FGE.21, FGE.21Rev4, includes the assessment of additional toxicity data for 
the supporting substance 5,6-dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113], 
which is considered to be structurally related to the candidate substances 2-butyl-4-
methyl(4H)pyrrolidino[1,2d]-1,3,5-dithiazine [FL-no: 15.042], dihydro-2,4,6-triethyl-1,3,5(4H)-
dithiazine [FL-no: 15.054], 2,4-dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine [FL-no: 15.055], 4,6-
dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine [FL-no: 15.057], 2-isobutyldihydro-4,6-dimethyl-
1,3,5-dithiazine [FL-no: 15.079] and ethyl thialdine [FL-no: 15.135], for which additional data were 
required. Furthermore, new in vitro genotoxicity studies have become available on the supporting 
substance 2-acetyl-2-thiazoline [FL-no: 15.010], which is considered to be structurally related to and a 
supportive substance for the candidate substance 2-methyl-2-thiazoline [FL-no: 15.086].  
Since the publication of the previous version of FGE.21, FGE.21Rev3, 18 of the original 59 candidate 
substances [FL-no: 15.037, 15.042, 15.043, 15.064, 15.070, 15.072, 15.077, 15.088, 15.090, 15.091, 
15.092, 15.094, 15.099, 15.106, 15.107, 15.114, 15.129 and 15.133]. for which additional data were 
required, are no longer supported by Industry for use as flavouring substances in Europe and will 
therefore not be considered any further. Accordingly, FGE.21Rev4 will only deal with 41 candidate 
substances. 
All candidate substances are five- or six-member sulphur-containing heterocyclic compounds, some of 
which also contain nitrogen. They have been divided into two main groups, those with an aromatic 
ring (33 candidate substances) (Group A) and those with a non-aromatic ring structure (eight candidate 
substances) (Group B). All are ring-substituted with one or more of the substituents alkyl, alkenyl, 
aryl, alcohol, keto and thio. For assessment purposes, the following further subdivision of groups (A) 
and (B) has been made: 
Group (A): Aromatic:  
(Subgroup A-Ia: Thiophene. The substance previously allocated to the group is no longer supported 
for use as flavouring substance in Europe by Industry.) 
Subgroup A-Ib: Thiophene derivatives with non-thiol-containing ring substituents.  
Subgroup A-Ic: Thiophene derivatives with thiol-containing ring substituents.  
Subgroup A-II: Thiazole derivatives.  
(Subgroup A-III: Benzothiazoles. The substance previously allocated to the group is no longer 
supported for use as flavouring substance in Europe by Industry.) 
Group (B): Non aromatic: 
(Subgroup B-I: Dihydrothiophenes. The substance previously allocated to the group is no longer 
supported for use as flavouring substance in Europe by Industry.) 
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Subgroup B-II: Thiazolines.  
(Subgroup B-III: Thiazolidines. The substances previously allocated to the group are no longer 
supported for use as flavouring substances in Europe by Industry.) 
Subgroup B-IV: Dithiazine derivatives.  
(Subgroup B-V: Dihydrothiazines. The substances previously allocated to the group are no longer 
supported for use as flavouring substances in Europe by Industry.) 
(Subgroup B-VI: Thiadiazine derivatives. The substance previously allocated to the group is no longer 
supported for use as flavouring substance in Europe by Industry.)  
Two of the 41 candidate substances possess one chiral centre [FL-no: 15.060, and 15.119], two 
substances possess two chiral centres [FL-no: 15.054 and 15.135] and three possess three chiral 
centres [FL-no: 15.055, 15.057 and 15.079]. The stereoisomeric composition has been specified for all 
substances.  
Thirty-four of the candidate substances belong to structural class II and seven belong to structural 
class III. 
Thirty-one of the candidate substances have been reported to occur naturally in a wide range of foods. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intake” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavour Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach. 
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
In accordance with the default MSDI approach, the flavouring substances in this FGE.21Rev4 have 
intakes in Europe ranging from 0.0012 to 5.7 µg/capita/day, which are below the thresholds of 
concern values for structural class II (540 µg/person/day) and structural class III (90 µg/person/day) 
substances. 
On the basis of the reported annual production volumes of the candidate substances as flavourings in 
Europe, the combined estimated daily per capita intakes, per subgroup and structural class range from 
0.14 to 8.0 µg. For none of the subgroups do the total combined intakes exceed the threshold of 
concern of 540 µg/person/day or of 90 µg/person/day for structural class II and III, respectively. 
The candidate substances are structurally related to 28 supporting substances evaluated by the JECFA 
at its 59th and 68th JECFA meetings. The total combined daily per capita intakes (in Europe) of 
candidate and supporting substances evaluated through the Procedure in each of the five subgroups for 
which supporting substances were available in the same structural class (SC) are: subgroup A-Ib (eight 
substances from class II) 3.4 µg; subgroup A-Ic (five substances from class III) 0.21 µg; subgroup A-
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II (37 substances from class II) 500 µg; subgroup B-II (two substances from SC II) 0.52 µg; subgroup 
B-IV (four substances from SC II) 4.5 µg.  
For none of the subgroups do the combined intakes exceed the thresholds of concern for compounds 
belonging to structural class II of 540 µg/person/day or to structural class III of 90 µg/person/day. 
It is concluded that the genotoxicity data are limited and that genotoxicity could not be assessed 
adequately for the flavouring substances in FGE.21Rev4. However, except for the two 3-thiazolines, 
2,4-dimethyl-3-thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 15.119], the 
genotoxicity data available do not preclude the evaluation of the remaining 39 candidate substances 
using the Procedure. 
The metabolism data available were insufficient to allow conclusions about the metabolic fate of the 
candidate substances, and accordingly the 39 candidate substances evaluated through the Procedure 
could not be anticipated to be metabolised to innocuous products. However, the Panel concluded that 
the evidence of binding to macromolecules from possible formation of electrophilic metabolites, (e.g. 
by either ring scission or S-oxidation) was not sufficiently strong to preclude the application of the 
Procedure. 
Toxicological data on both candidate and supporting substances were limited and did not include 
information about chronic or reproductive toxicity, with the exception of a combined repeat dose and 
reproduction and developmental toxicity study on the structurally related thiophene [former FL-no: 
15.106]. Valid toxicological data which could provide an adequate margin of safety compared with the 
intakes from use as flavouring substances were only available for the candidate substances from 
subgroup A-Ic (thiophenes with thiol-containing ring substituents), subgroup A-II (thiazoles), 
subgroup B-II (only the 2-thiazoline) and subgroup B-IV (dithiazines). 
For the remaining candidate substances belonging to the subgroup of thiophenes with non-thiol-
containing ring substituents (A-Ib), the Panel concluded that there were insufficient data available to 
provide margins of safety from their use as flavouring substances and that additional toxicity data are 
needed. 
It is considered that 32 candidate substances evaluated through the Procedure [FL-no: 15.038, 15.039, 
15.044, 15.050, 15.051, 15.052, 15.054, 15.055, 15.057, 15.058, 15.061, 15.062, 15.063, 15.067, 
15.068, 15.069, 15.071, 15.078, 15.079, 15.080, 15.082, 15.084, 15.085, 15.086, 15.087, 15.089, 
15.098, 15.108, 15.115, 15.116, 15.118 and 15.135] are not of safety concern at their estimated levels 
of intake based on the MSDI approach, whereas for seven candidate substances [FL-no: 15.040, 
15.045, 15.074, 15.076, 15.093, 15.096 and 15.097], additional toxicological data are required. 
Furthermore, for two substances [FL-no: 15.060 and 15.119] the Panel concluded that additional 
genotoxicity data are required. 
The estimated intakes, based on the mTAMDI, for the 32 candidate substances assigned to structural 
class II and evaluated using the Procedure, range from 78 to 220 µg/person/day, which is below the 
threshold of concern for structural class II of 540 µg/person/day. The estimated intakes based on the 
mTAMDI of the seven candidate substances assigned to structural class III and evaluated through the 
Procedure ranged from 78 to 250 µg/person/day. For the candidate substances [FL-no:, 15.055 and 
15.135] the estimated intakes are above the threshold of concern for structural class III substances of 
90 µg/person/day. For two candidate substances [FL-no: 15.057 and 15.079], assigned to structural 
class III, no use levels were provided at all. Therefore, more reliable exposure data are required for 
[FL-no: 15.055, 15.057, 15.079, and 15.135]. On the basis of such additional data, these flavouring 
substances should be re-evaluated using the Procedure. 
In order to determine whether the conclusion for the 39 candidate substances which have been 
evaluated using the Procedure can be applied to the materials of commerce, it is necessary to consider 
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the available specifications. Adequate specifications including purity and identity for the materials of 
commerce have been provided for all 39 flavouring substances evaluated through the Procedure.  
Thus, for seven candidate substances [FL-no: 15.040, 15.045, 15.074, 15.076, 15.093, 15.096 and 
15.097] the Panel considered that additional toxicity data are needed. Furthermore, for two substances 
[FL-no: 15.060 and 15.119] the Panel concluded that additional genotoxicity data are required.  
For the remaining 32 flavouring substances [FL-no: 15.038, 15.039, 15.044, 15.050, 15.051, 15.052, 
15.054, 15.055, 15.057, 15.058, 15.061, 15.062, 15.063, 15.067, 15.068, 15.069, 15.071, 15.078, 
15.079, 15.080, 15.082, 15.084, 15.085, 15.086, 15.087, 15.089, 15.098, 15.108, 15.115, 15.116, 
15.118 and 15.135], evaluated using the Procedure, the Panel concluded that they would present no 
safety concern at their estimated levels of intake based on the MSDI approach. 
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 20084 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/20125. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20006. 
EFSA has evaluated 59 flavouring substances in the flavouring group evaluation 21 (FGE.21) and its 
three revisions. The last opinion was adopted on 24 November 2011. EFSA concluded in its opinion 
that for 26 substances additional toxicological data are. 
The requested information on one representative material, 5,6-dihydro-2,4,6,tris(2-methylpropyl)-4H-
l,3,5-dithiazine [FL-no: 15.113] has now been submitted by the European Flavour Association. This 
information is intended to cover the re-evaluation of this substance and the re-evaluation of the 
following five substances in FGE.21: 
Dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine [FL-no: 15.054]  
2,4-Dimethyl(4H)pyrrolidino[l,2e]-1,3,5-dithiazine [FL-no: 15.055],  
4,6-Dimethyl-2-(l-methylethyl)dihydro-l,3,5-dithiazine [FL-no: 15.057],  
2-Isobutyldihydro-4,6-dimethyl-l,3,5-dithiazine [FL-no: 15.079],  
2-methyl-2-thiazoline [FL-no: 15.086] and ethyl thialdine [FL-no 15.135] 
 
In addition, requested information on another representative material, 2-acetyl-2-thiazoline [FL-no: 
15.010], has now been submitted by the European Flavour Association. This information is intended 
to cover the re-evaluation of 2-methyl-2-thiazoline [FL-no: 15.086] from FGE.21. 
The Commission asks EFSA to evaluate this new information.  
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests European Food Safety Authority (EFSA) to carry out a safety 
assessment on the following six flavouring substances: dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine 
[FL-no: 15.054], 2,4-dimethyl(4H)pyrrolidino[l,2e]-1,3,5-dithiazine [FL-no: 15.055], 4,6-dimethyl-2-
(l-methylethyl)dihydro-l,3,5-dithiazine [FL-no: 15.057], 2-isobutyldihydro-4,6-dimethyl-l,3,5-
dithiazine [FL-no: 15.079], 2-methyl-2-thiazoline [FL-no: 15.086] and ethyl thialdine [FL-no 15.135] 
in accordance with Commission Regulation (EC) No 1565/2000. 
                                                     
4  Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and  
 certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No  
 1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. Official Journal of the European  
 Communities 31.12.2008, L 354/34-50. 
5  EC (European Commission), 2012. Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting  
 the list of flavouring substances provided for by Regulation (EC) No 2232/96 of the European Parliament and of the  
 Council, introducing it in Annex I to Regulation (EC) No 1334/2008 of the European Parliament and of the Council and  
 repealing Commission Regulation (EC) No 1565/2000 and Commission Decision 1999/217/EC. Official Journal of the  
 European Communities 2.10.2012, L 267, 1-161.OJ L 267, 2.10.2012, p. 1. 
6  Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an  
 evaluation programme in application of Regulation (EC) No 2232/96. Official Journal of the European Communities  
 19.7.2000, L 180, 8-16. 
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ASSESSMENT 
1. History of the Evaluation of the Substances in the Present FGE  
In FGE.21 and the first revision (FGE.21Rev1), the Panel considered that additional toxicity data were 
needed for 23 of the substances (Subgroups A-Ia, A-Ib, A-III, B-I, B-IV and B-VI) evaluated through 
the Procedure, as no adequate toxicity study from which a No Observed Adverse Effect Level 
(NOAEL) could be established, for either the candidate substances or  supporting substances was 
available.  
In the second revision of FGE.21 (FGE.21Rev2), additional toxicity data and metabolism data became 
available (Flavouring Industry, 2010a) for two substances, thiophene [FL-no: 15.106] from subgroup 
A-Ia and sec-pentylthiophene [FL-no: 15.096] from subgroup A-Ibbut the Panel concluded that the 
data were not valid for the purposes of establishing a NOAEL. Further, information on the 
stereoisomeric composition of nine substances [FL-no: 15.042, 15.054, 15.055, 15.060, 15.077, 
15.090, 15.099, 15.119 and 15.129] was provided by European Flavour and Fragrance Association 
(EFFA) (EFFA, 2010; EFFA, 2011b). 
The third revision of FGE.21 (FGE.21Rev3) included the assessment of three additional substances, 
4,6-dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine [FL-no: 15.057], 2-isobutyldihydro-4,6-
dimethyl-1,3,5-dithiazine [FL-no: 15.079] and ethyl thialdine [FL-no: 15.135]. For these three 
candidate substances [FL-no: 15.057, 15.079 and 15.135], a NOAEL could not be derived for the 
substance or a structurally related substance. Accordingly, additional data were required for these 
three flavouring substances. 
Since the publication of FGE.21Rev3, 18 of the 59 candidate substances [FL-no: 15.037, 15.042, 
15.043, 15.064, 15.070, 15.072, 15.077, 15.088, 15.090, 15.091, 15.092, 15.094, 15.099, 15.106, 
15.107, 15.114, 15.129 and 15.133] are no longer supported for use as flavouring substances in Europe 
by Industry (EFSA, 2011; DG SANCO, 2013) and will therefore not be considered any further. The 18 
substances are listed here below. 
FL-no EU Register name 
15.037 2-Acetyl-3-methylthiophene 
15.042 2-Butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-dithiazine 
15.043 2-Butyl-5-ethylthiophene 
15.064 2,5-Dimethylthiophene 
15.070 2-Ethyl-5-methylthiophene 
15.072 2-Ethylthiophene 
15.077 4-Hydroxy-2,5-dimethylthiophen-3(2H)-one 
15.088 2-Methyl-4,5-benzothiazole 
15.090 2-Methylthiazolidine 
15.091 2-Methylthiophene 
15.092 3-Methylthiophene 
15.094 2-Pentanoylthiophene 
15.099 2-Propylthiazolidine 
15.106 Thiophene 
15.107 Thiophene-2-carbaldehyde 
15.114 6-Acetyl-2,3-dihydro-1,4-thiazine 
15.129 Tetrahydro-2,4,6-trimethyl-1,3,5(2H)-thiadiazine 
15.133 5-Acetyl-2,3-dihydro-1,4-thiazine 
These 18 substances will be excluded in the following text except in Tables 1 and 7. Information in the 
text on these substances will be kept only if relevant for the remaining candidate substances. 
As a consequence of this, the following supporting substance has been deleted from this revision: 
FL-no EU Register name Structural formula 
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JECFA no  
15.016 
1040 
Benzothiazole 
N
S
 
The table below gives information on publication dates and links to the published versions.  
FGE Opinion adopted by 
EFSA 
Link No. of 
candidate 
substances 
FGE.21 8 February 2007 http://www.efsa.europa.eu/EFSA/efsa_locale-
1178620753812_1178694698331.htm 
54 
FGE.21Rev1 26 March 2009 http://www.efsa.europa.eu/en/scdocs/scdoc/1023.htm 56 
FGE.21Rev2 4 February 2011 http://www.efsa.europa.eu/en/efsajournal/doc/1989.pdf 56 
FGE.21Rev3 23 November 2011 http://www.efsa.europa.eu/en/efsajournal/pub/2457.htm 59 
FGE.21Rev4 24 October 2013  41 
The present revision of FGE.21, FGE.21Rev4, includes a re-evaluation of six candidate substances, 
dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine [FL-no: 15.054], 2,4-dimethyl(4H)pyrrolidino[1,2e]-1,3,5-
dithiazine [FL-no: 15.055], 4,6-dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine [FL-no: 15.057], 
2-isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine [FL-no: 15.079], 2-methyl-2-thiazoline [FL-no: 
15.086] and ethyl thialdine [FL-no: 15.135]. 
Additional data from a 14-day and a 90-day dietary rat study for the supporting substance 5,6-dihydro-
2,4,6,tris(2-methylpropyl)-4H-l,3,5-dithiazine [FL-no: 15.113] (Bauter, 2012; Bauter, 2013) and 
mutagenicity studies (reverse mutation and micronucleus induction) for the supporting substance 2-
acetyl-2-thiazoline [FL-no: 15.010] have now become available (Mc Garry, 2012; Watters, 2012). The 
substance [FL-no: 15.010] from FGE.93Rev1 is representative of the group of 2-thiazolines and 
supports the substance [FL-no: 15.086] in this FGE and has therefore been included here as well, 
whereas [FL-no: 15.113] from FGE.76Rev1 supports [FL-no: 15.054, 15.055, 15.057, 15.079 and 
15.135] in this FGE. 
Since the publication of FGE.21Rev3, new information on European production figures has been 
provided by EFFA for five substances [FL-no: 15.054, 15.055, 15.057, 15.079 and 15.135] (EFFA, 
2013b). Furthermore, new information from Industry on missing stereoisomeric composition for [FL-
no: 15.057, 15.079 and 15.135] is also included in the present revision (EFFA, 2013b). 
2. Presentation of the Substances in Flavouring Group Evaluation 21, Revision 4 
2.1. Description 
The present Flavouring Group Evaluation 21, Revision 4 (FGE.21Rev4), using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000 (The Procedure – shown in schematic 
form in Appendix A of this FGE), deals with 41 flavouring substances (candidate substances) from 
chemical groups 29 and 30, Annex I of Commission Regulation (EC) No 1565/2000. The candidate 
substances in FGE.21Rev4 fall into the chemical groups of thiophene derivatives (S-containing), 
thiazoles (S- and N-containing), thiazolines (S- and N- containing) and dithiazines (S- and N-
containing) (Table 1 and Table 5 in Section 5). 
The candidate substances as well as their chemical Register names, FLAVIS- (FL-no), Chemical 
Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract Manufacturers 
Association- (FEMA-) numbers, structure and specifications, are listed in Table 1. 
A summary of the outcome of the safety evaluation of the candidate substances are listed in Table 7. 
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The candidate substances are structurally closely related to 28 flavouring substances (supporting 
substances) evaluated at the 59th and 68th JECFA meetings (JECFA, 2002a; JECFA, 2003; JECFA, 
2007; JECFA, 2008) in the group of “Sulphur–containing heterocyclic compounds”. Two of these 
supporting substances are mixtures (one of two isomeric isobutyl-substituted and one of two isomeric 
isopropyl-substituted dimethyldihydrodithiazine derivatives) and are not included in the Register 
(Table 8). 
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SUMMARY OF SPECIFICATION DATA 
Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
15.037 
 
2-Acetyl-3-methylthiophene 
S
O
 
 
11590 
13679-72-6 
Liquid 
C7H8OS 
140.20 
Practically 
insoluble or 
insoluble 
Freely soluble 
216 
 
MS 
95 % 
1.558-1.564 
1.130-1.136 
 
No longer 
supported by 
Industry (EFSA, 
2011). 
15.038 
 
2-Acetyl-4-methylthiazole 
N
S
O
 
 
11589 
7533-07-5 
Solid 
C6H7NOS 
141.19 
Practically 
insoluble or 
insoluble 
Freely soluble 
95 (16 hPa) 
34 
MS 
95 % 
n.a. 
n.a. 
 
 
15.039 
 
2-Acetyl-5-methylthiazole 
N
S
O
 
 
 
59303-17-2 
Solid 
C6H7NOS 
141.19 
Practically 
insoluble or 
insoluble 
Freely soluble 
93 (16 hPa) 
30 
MS 
95 % 
n.a. 
n.a. 
 
 
15.040 
 
2-Acetylthiophene 
S
O
 
 
11728 
88-15-3 
Solid 
C6H6OS 
126.17 
Practically 
insoluble or 
insoluble 
Freely soluble 
213 
34 
MS 
98 % 
1.563-1.569 
1.164-1.171 
 
 
15.042 
 
2-Butyl-4-
methyl(4H)pyrrolidino[1,2d]
-1,3,5-dithiazine 
S N
S
 
 
 
132344-97-9 
Solid 
C11H21NS2 
231.42 
Practically 
insoluble or 
insoluble 
Freely soluble 
304 
164 
NMR 
95 % 
n.a. 
n.a. 
 
No longer 
supported by 
Industry (EFSA, 
2011). Mixture of 
diastereoisomers 
(EFFA, 2010). 
CASrn in Register 
does not specify 
stereoisomeric 
composition. 
Compostition of 
stereoisomeric 
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
mixture to be 
specified. 
15.043 
 
2-Butyl-5-ethylthiophene S
 
 
11596 
54411-06-2 
Solid 
C10H16S 
168.30 
Practically 
insoluble or 
insoluble 
Freely soluble 
231 
54 
MS 
95 % 
n.a. 
n.a. 
 
No longer 
supported by 
Industry (EFSA, 
2011). 
15.044 
 
2-Butylthiazole 
N
S
 
 
11597 
37645-61-7 
Solid 
C7H11NS 
141.23 
Practically 
insoluble or 
insoluble 
Freely soluble 
212 
79 
NMR 
95 % 
n.a. 
n.a. 
 
 
15.045 
 
2-Butylthiophene S
 
 
 
1455-20-5 
Liquid 
C8H12S 
140.24 
Practically 
insoluble or 
insoluble 
Freely soluble 
182 
 
MS 
95 % 
1.504-1.510 
0.951-0.957 
 
 
15.050 
 
2,5-Diethyl-4-methylthiazole 
N
S
 
 
 
41981-71-9 
Solid 
C8H13NS 
155.26 
Practically 
insoluble or 
insoluble 
Freely soluble 
85 (20 hPa) 
115 
MS 
95 % 
n.a. 
n.a. 
 
 
15.051 
 
2,5-Diethyl-4-propylthiazole 
N
S
 
 
 
4276-68-0 
Solid 
C10H17NS 
183.31 
Practically 
insoluble or 
insoluble 
Freely soluble 
72 (21 hPa) 
139 
NMR 
95 % 
n.a. 
n.a. 
 
 
15.052 
 
2,5-Diethylthiazole 
N
S
 
 
 
15729-76-7 
Solid 
C7H11NS 
141.23 
Practically 
insoluble or 
insoluble 
Freely soluble 
187 
92 
MS 
95 % 
n.a. 
n.a. 
 
 
15.054 
 
Dihydro-2,4,6-triethyl-
1,3,5(4H)-dithiazine 
S NH
S
 
 
 
54717-17-8 
Solid 
C9H19NS2 
205.38 
Practically 
insoluble or 
insoluble 
Freely soluble 
287 
188 
MS 
95 % 
n.a. 
n.a. 
 
Mixture of 
diastereoisomers 
(EFFA, 2010). 
Mixture of 
isomers ((R/R), 
(R/S), (S/R) & 
(S/S) at equal 
ratio, i.e. 25 % of 
each) (EFFA, 
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
2011b). 
15.055 
1763 
2,4-
Dimethyl(4H)pyrrolidino[1,
2e]-1,3,5-dithiazine S N
S  
4321 
 
116505-60-3 
Solid 
C8H15NS2 
189.34 
Practically 
insoluble or 
insoluble 
Freely soluble 
235 
130 
MS 
95 % 
n.a. 
n.a. 
 
Register name to 
be changed to 
[2S-(2a,4a,8ab)] 
2,4-
Dimethyl(4H)pyrr
olidino[1,2e]-
1,3,5-dithiazine 
(EFFA, 2010). 
15.057 
 
4,6-Dimethyl-2-(1-
methylethyl)dihydro-1,3,5-
dithiazine 
HN
S
S
 
3782 
 
104691-40-9 
Liquid 
C8H17NS2 
191.36 
Slightly 
soluble 
Soluble 
109 (0.23hPa) 
 
MS 
71 % 
1.496-1.500 
0.951-0.959 
 
Mixture of 4 
diastereoisomers 
(25 % of each) 
(EFFA, 2013b). 
At least 44 % 2-
Isopropyl-4,6-
dimethyl and 27 
% 4-Isopropyl-
2,6-dimethyl; sec 
comp at least 24 
% 2,4,6-
Trimethyldihydro-
; 6-Methyl-2,4-
diisopropyl-; 4-
Methyl-2,6-
diisopropyl-, 
2,4,6-
Triisopropyl-
dihydro-1,3,5-
dithiazine (EFFA, 
2011c). 
15.058 
 
4,5-Dimethyl-2-ethylthiazole 
N
S
 
 
 
873-64-3 
Solid 
C7H11NS 
141.23 
Practically 
insoluble or 
insoluble 
Freely soluble 
185 
104 
MS 
96 % 
n.a. 
n.a. 
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
15.060 
 
2,4-Dimethyl-3-thiazoline 
N
S
 
 
 
60755-05-7 
Solid 
C5H9NS 
115.19 
Practically 
insoluble or 
insoluble 
Freely soluble 
52 (15 hPa) 
102 
MS 
95 % 
n.a. 
n.a. 
 
Racemate (EFFA, 
2010). 
15.061 
 
2,5-Dimethyl-4-ethylthiazole 
N
S
 
 
 
32272-57-4 
Solid 
C7H11NS 
141.23 
Practically 
insoluble or 
insoluble 
Freely soluble 
185 
104 
MS 
95 % 
n.a. 
n.a. 
 
 
15.062 
 
2,4-Dimethylthiazole 
N
S
 
 
11605 
541-58-2 
Solid 
C5H7NS 
113.18 
Practically 
insoluble or 
insoluble 
Freely soluble 
145 
69 
MS 
95 % 
n.a. 
n.a. 
 
 
15.063 
1758 
2,5-Dimethylthiazole 
N
S
 
 
 
4175-66-0 
Solid 
C5H7NS 
113.18 
Practically 
insoluble or 
insoluble 
Freely soluble 
152 
69 
MS 
95 % 
n.a. 
n.a. 
 
 
15.064 
 
2,5-Dimethylthiophene S
 
 
11609 
638-02-8 
Liquid 
C6H8S 
112.19 
Practically 
insoluble or 
insoluble 
Freely soluble 
135 
 
MS 
95 % 
1.508-1.514 
0.982-0.988 
 
No longer 
supported by 
Industry (DG 
SANCO, 2013). 
15.067 
 
4-Ethyl-2-methylthiazole 
N
S
 
 
 
32272-48-3 
Solid 
C6H9NS 
127.20 
Practically 
insoluble or 
insoluble 
Freely soluble 
91 (89 hPa) 
80 
MS 
95 % 
n.a. 
n.a. 
 
 
15.068 
 
5-Ethyl-2-methylthiazole 
N
S
 
 
 
19961-52-5 
Solid 
C6H9NS 
127.20 
Practically 
insoluble or 
insoluble 
Freely soluble 
170 
80 
MS 
95 % 
n.a. 
n.a. 
 
 
15.069 
 
4-Ethyl-5-methylthiazole 
N
S
 
 
 
52414-91-2 
Solid 
C6H9NS 
127.20 
Practically 
insoluble or 
insoluble 
Freely soluble 
174 
80 
MS 
95 % 
n.a. 
n.a. 
 
 
15.070 
 
2-Ethyl-5-methylthiophene S
 
 
 
40323-88-4 
Liquid 
C7H10S 
126.22 
Practically 
insoluble or 
insoluble 
158 
 
MS 
1.503-1.509 
0.963-0.970 
 
No longer 
supported by 
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
Freely soluble 97 % Industry (EFSA, 
2011). 
15.071 
 
2-Ethylthiazole 
N
S
 
 
 
15679-09-1 
Liquid 
C5H7NS 
113.18 
Practically 
insoluble or 
insoluble 
Freely soluble 
148 
 
MS 
95 % 
1.511-1.517 
1.058-1.064 
 
 
15.072 
 
2-Ethylthiophene S
 
 
11614 
872-55-9 
Liquid 
C6H8S 
112.19 
Practically 
insoluble or 
insoluble 
Freely soluble 
133 
 
MS 
95 % 
1.510-1.516 
0.989-0.995 
 
No longer 
supported by 
Industry (DG 
SANCO, 2013). 
15.074 
 
5-Ethylthiophene-2-
carbaldehyde 
S
O
 
 
 
36880-33-8 
Solid 
C7H8OS 
140.20 
Practically 
insoluble or 
insoluble 
Freely soluble 
104 (12 hPa) 
62 
MS 
95 % 
n.a. 
n.a. 
 
 
15.076 
1764 
2-Hexylthiophene S
 
4137 
11616 
18794-77-9 
Solid 
C10H16S 
168.30 
Practically 
insoluble or 
insoluble 
Freely soluble 
92 (13 hPa) 
41 
MS 
95 % 
n.a. 
n.a. 
 
 
15.077 
 
4-Hydroxy-2,5-
dimethylthiophen-3(2H)-one 
S
HO O  
 
 
26494-10-0 
Solid 
C6H8O2S 
144.19 
Practically 
insoluble or 
insoluble 
Freely soluble 
296 
133 
MS 
95 % 
n.a. 
n.a. 
 
No longer 
supported by 
Industry (EFSA, 
2011). Racemate 
(EFFA, 2010). 
15.078 
 
2-Isobutyl-4,5-
dimethylthiazole 
N
S
 
 
11617 
53498-32-1 
Solid 
C9H15NS 
169.29 
Practically 
insoluble or 
insoluble 
Freely soluble 
267 
112 
MS 
97 % 
n.a. 
n.a. 
 
 
15.079 
 
2-Isobutyldihydro-4,6-
dimethyl-1,3,5-dithiazine 
S
N
H
S
 
3781 
 
101517-87-7 
Liquid 
C9H19NS2 
205.39 
Slightly 
soluble 
Soluble 
115 (0.33 hPa) 
 
MS 
82 % 
1.488-1.492 
0.961-0.967 
 
Mixture of 
diastereoisomers, 
each of them 
racemic (EFFA, 
2013b). At least 
64 % 2-isobutyl-
4,6-dimethyl and 
18 % 4-Isobutyl-
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
2,6-dimethyl; sec. 
components at 
least 13 %  2,4,6-
trimethyl-; 2,4-
diisobutyl-6-
methyl-; 2,6-
dimethyl-4-
butyldihydro-
1,3,5-dithiazine; 
substituted 1,3,5-
thiadiazine 
(EFFA, 2011c). 
15.080 
 
2-Isopropyl-4,5-
dimethylthiazole 
N
S
 
 
 
53498-30-9 
Solid 
C8H13NS 
155.26 
Practically 
insoluble or 
insoluble 
Freely soluble 
244 
101 
MS 
95 % 
n.a. 
n.a. 
 
 
15.082 
 
3-Mercaptothiophene S
SH  
 
 
7774-73-4 
Liquid 
C4H4S2 
116.20 
Slightly 
soluble 
Freely soluble 
171 
 
MS 
95 % 
1.617-1.623 
1.248-1.254 
 
 
15.084 
 
5-Methyl-2-pentylthiazole 
N
S
 
 
 
86290-21-3 
Solid 
C9H15NS 
169.26 
Practically 
insoluble or 
insoluble 
Freely soluble 
262 
114 
NMR 
95 % 
n.a. 
n.a. 
 
 
15.085 
 
4-Methyl-2-
propionylthiazole 
N
S
O
 
 
11622 
13679-83-9 
Solid 
C7H9NOS 
155.21 
Practically 
insoluble or 
insoluble 
Freely soluble 
86 (12 hPa) 
142 
NMR 
95 % 
n.a. 
n.a. 
 
 
15.086 
 
2-Methyl-2-thiazoline 
N
S
 
 
 
2346-00-1 
Solid 
C4H7NS 
101.17 
Slightly 
soluble 
Freely soluble 
144 
62 
MS 
95 % 
n.a. 
n.a. 
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
15.087 
 
2-Methyl-3-
mercaptothiophene 
S
SH  
 
 
2527-76-6 
Solid 
C5H6S2 
130.22 
Slightly 
soluble 
Freely soluble 
73 (15 hPa) 
27 
MS 
95 % 
n.a. 
n.a. 
 
 
15.088 
 
2-Methyl-4,5-benzothiazole 
N
S
 
 
 
120-75-2 
Liquid 
C8H7NS 
149.21 
Practically 
insoluble or 
insoluble 
Freely soluble 
238 
 
MS 
95 % 
1.612-1.618 
1.173-1.179 
 
No longer 
supported by 
Industry (EFSA, 
2011). 
15.089 
 
2-Methylthiazole 
N
S
 
 
11626 
3581-87-1 
Liquid 
C4H5NS 
99.15 
Slightly 
soluble 
Freely soluble 
128 
 
MS 
95 % 
1.511-1.517 
1.109-1.116 
 
 
15.090 
 
2-Methylthiazolidine 
NH
S
 
 
 
24050-16-6 
Liquid 
C4H9NS 
103.18 
Slightly 
soluble 
Freely soluble 
160 
 
MS 
95 % 
1.522-1.528 
1.519-1.525 
 
No longer 
supported by 
Industry (EFSA, 
2011). Racemate 
(EFFA, 2010). 
15.091 
 
2-Methylthiophene S
 
 
11631 
554-14-3 
Liquid 
C5H6S 
98.16 
Practically 
insoluble or 
insoluble 
Freely soluble 
112 
 
MS 
97 % 
1.516-1.523 
1.013-1.022 
 
No longer 
supported by 
Industry (DG 
SANCO, 2013). 
15.092 
 
3-Methylthiophene S
 
 
11632 
616-44-4 
Liquid 
C5H6S 
98.16 
Practically 
insoluble or 
insoluble 
Freely soluble 
115 
 
MS 
95 % 
1.514-1.520 
1.018-1.024 
 
No longer 
supported by 
Industry (DG 
SANCO, 2013). 
15.093 
 
2-Octylthiophene S
 
 
 
880-36-4 
Solid 
C12H20S 
196.35 
Practically 
insoluble or 
insoluble 
Freely soluble 
259 
64 
MS 
95 % 
n.a. 
n.a. 
 
 
15.094 
 
2-Pentanoylthiophene 
S
O
 
 
 
53119-25-8 
Solid 
C9H12OS 
168.26 
Practically 
insoluble or 
insoluble 
Freely soluble 
257 
80 
MS 
95 % 
n.a. 
n.a. 
 
No longer 
supported by 
Industry (EFSA, 
2011). 
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
15.096 
2106 
sec-Pentylthiophene S
 
4387 
11634 
4861-58-9 
Liquid 
C9H14S 
154.27 
Practically 
insoluble or 
insoluble 
Freely soluble 
201 
 
MS 
95 % 
1.495-1.501 
0.940-0.946 
 
Register name to 
be changed to 2-
Pentylthiophene 
(EFFA). 
15.097 
 
2-Propionylthiophene 
S
O
 
 
11635 
13679-75-9 
Solid 
C7H8OS 
140.20 
Practically 
insoluble or 
insoluble 
Freely soluble 
225 
57 
MS 
95 % 
n.a. 
n.a. 
 
 
15.098 
 
2-Propylthiazole 
N
S
 
 
 
17626-75-4 
Solid 
C6H9NS 
127.20 
Practically 
insoluble or 
insoluble 
Freely soluble 
172 
78 
MS 
95 % 
n.a. 
n.a. 
 
 
15.099 
 
2-Propylthiazolidine 
NH
S
 
 
 
24050-10-0 
Solid 
C6H13NS 
131.24 
Practically 
insoluble or 
insoluble 
Freely soluble 
75 (13 hPa) 
84 
MS 
95 % 
n.a. 
n.a. 
 
No longer 
supported by 
Industry (EFSA, 
2011). Racemate 
(EFFA, 2010). 
15.106 
 
Thiophene S
 
 
11647 
110-02-1 
Liquid 
C4H4S 
84.14 
Practically 
insoluble or 
insoluble 
Freely soluble 
84 
 
MS 
95 % 
1.525-1.531 
1.062-1.068 
 
No longer 
supported by 
Industry (EFSA, 
2011). 
15.107 
 
Thiophene-2-carbaldehyde 
S
O
 
 
11874 
98-03-3 
Liquid 
C5H4OS 
112.15 
Slightly 
soluble 
Freely soluble 
198 
 
MS 
95 % 
1.585-1.592 
1.216-1.225 
 
No longer 
supported by 
Industry (EFSA, 
2011). 
15.108 
 
2-Thiophenemethanethiol S
SH
 
 
 
6258-63-5 
Liquid 
C5H6S2 
130.22 
Slightly 
soluble 
Freely soluble 
82 (16 hPa) 
 
MS 
95 % 
1.571-1.578 
1.165-1.171 
 
 
15.114 
 
6-Acetyl-2,3-dihydro-1,4-
thiazine 
N
H
S
O
 
4296 
 
101417-25-8 
Solid 
C6H9NOS 
143.2 
Sparringly 
soluble 
Freely soluble 
242 
126 
NMR 
95 % 
n.a. 
n.a. 
 
No longer 
supported by 
Industry (EFSA, 
2011). 
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
15.115 
 
2-Isobutyl-4-methyl thiazole 
N
S
 
 
 
61323-24-8 
Solid 
C8H13NS 
155.26 
Slightly 
soluble 
Freely soluble 
189 
88 
MS 
95 % 
n.a. 
n.a. 
 
Register name to 
be changed to 2-
Isobutyl-4-
methylthiazole. 
15.116 
 
2-Acetyl-4-ethylthiazole 
N
S
O
 
 
 
233665-91-3 
Solid 
C7H9NOS 
155.22 
Slightly 
soluble 
Freely soluble 
270 
142 
NMR 
95 % 
n.a. 
n.a. 
 
 
15.118 
 
4-Butylthiazole 
N
S
 
 
 
53833-33-3 
Solid 
C7H11NS 
141.23 
Practically 
insoluble or 
insoluble 
Freely soluble 
212 
79 
MS 
95 % 
n.a. 
n.a. 
 
 
15.119 
 
2-Isobutyl-3-thiazoline 
N
S
 
 
 
39800-92-5 
Solid 
C7H13NS 
143.25 
Very slightly 
soluble 
Freely soluble 
197 
80 
MS 
95 % 
n.a. 
n.a. 
 
Racemate (EFFA, 
2011b). 
15.129 
 
Tetrahydro-2,4,6-trimethyl-
1,3,5(2H)-thiadiazine 
HN NH
S
 
 
 
53897-63-5 
Solid 
C6H14N2S 
146 
Soluble 
Soluble 
216-266 (1 hPa) 
65-70 
 
99 % 
n.a. 
n.a. 
ID 6). 
No longer 
supported by 
Industry (EFSA, 
2011). Mixture of 
diastereoisomers 
(EFFA, 2010). 
Mixture of 
isomers ((R/R), 
(R/S), (S/R) & 
(S/S) at equal 
ratio, i.e. 25 % of 
each) (EFFA, 
2011b). 
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Table 1:  Specification Summary of the Substances in the Flavouring Group Evaluation 21, Revision 4 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
15.133 
1766 
5-Acetyl-2,3-dihydro-1,4-
thiazine 
S
N
H
O  
 
 
164524-93-0 
Solid 
C6H9NOS 
143 
Soluble 
Soluble 
289+/-30 
67-69 
 
98 % 
n.a. 
n.a. 
ID 6). 
No longer 
supported by 
Industry (EFSA, 
2011). 
15.135 
 
Ethyl thialdine 
S
N
H
S
 
4667 
 
54717-14-5 
Liquid 
C7H15NS2 
177.33 
Poorly 
soluble 
Soluble 
75 
 
IR NMR MS 
90 % 
1.5344-1.5544 
1.0745-1-0765 
 
Mixture of 
diastereoisomers, 
each of them 
racemic (EFFA, 
2013b). Min assay 
value 90 %. 
Remaining 
impurities: 3,5-
diethyl-1,2,4-
trithiolane (< 5 
%), thialdine (< 2 
%), other 
impurities (< 3 %) 
(Flavour Industry, 
2011). 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 % ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
6)  ID: Missing identification test. 
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2.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different and they may have different chemical properties resulting in possible 
variability in their absorption, distribution, metabolism, elimination and toxicity. Thus, information 
must be provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number, etc.). 
Two of the 41 candidate substances possess one chiral centre [FL-no: 15.060, and 15.119], two 
possess two chiral centres [FL-no: 15.054 and 15.135] and three possess three chiral centres [FL-no: 
15.055, 15.057 and 15.079]. The stereoisomeric composition has been specified for all substances 
(EFFA, 2010; EFFA, 2011b; EFFA, 2013b) (see Table 1). 
2.3. Natural Occurrence in Food 
Thirty-one candidate substances have been reported to occur naturally in one or more of the following 
food items: shellfish, shrimps, squid, pork, beef, lamb, chicken, vegetables, peanut, wheaten bread, 
butter, cheese, tea, coffee, cocoa and various types of alcoholic beverages. Quantitative data on the 
natural occurrence in foods have been reported for nine of these substances (TNO, 2000; TNO, 2010; 
TNO, 2011), see Table 2. 
Table 2:  Candidate substances reported to occur in food (TNO, 2000; TNO, 2011) 
FL-no: Name: Quantitative data reported 
15.038 2-Acetyl-4-methylthiazole 0.02 mg/kg in kohlrabi 
15.040 2-Acetylthiophene 
Up to 1.25 mg/kg in coffee, 0.02 mg/kg in kohlrabi,  
up to 0.00002 mg/kg in pork (grilled, roasted) 
15.061 2,5-Dimethyl-4-ethylthiazole 0.00001 mg/kg in pork (grilled, roasted) 
15.062 2,4-Dimethylthiazole Up to 0.00004 mg/kg in pork (grilled, roasted) 
15.069 4-Ethyl-5-methylthiazole Up to 0.00001 mg/kg in pork (grilled, roasted) 
15.076 2-Hexylthiophene Up to 0.002 mg/kg in guinea hen 
15.096 2-Pentylthiophene 0.001 mg/kg in chicken (roasted) 
15.097 2-Propionylthiophene 0.8 mg/kg in coffee 
15.135 Ethyl thialdine 0.02 mg/kg in krill, up to 0.3 mg/kg in shrimps 
 
Ten of the candidate substances have not been reported to occur naturally in any food items according 
to TNO (TNO, 2000; TNO, 2010; TNO, 2011), see Table 3. 
Table 3:  Candidate Substances Not Reported to Occur in Food (TNO, 2000; TNO, 2010; TNO, 
2011) 
FL-no: Name: 
06 15.044 2-Butylthiazole 
15.055 2,4-Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine 
15.074 5-Ethylthiophene-2-carbaldehyde 
15.079 2-Isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine 
15.082 3-Mercaptothiophene 
15.087 2-Methyl-3-mercaptothiophene 
15.108 2-Thiophenemethanethiol 
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15.115 2-Isobutyl-4-methylthiazole 
15.116 2-Acetyl-4-ethylthiazole 
15.119 2-Isobutyl-3-thiazoline 
 
3. Specifications 
Purity criteria for the candidate substances have been provided by the flavouring industry (EFFA, 
2004d; EFFA, 2011a; Flavour Industry, 2010b).  
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000, the 
information is adequate for all 41 substances (see Section 2.2 and Table 1). 
4. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties in 
the underreporting correction factor and to uncertainties in the percentage of consumers, the reliability 
of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported). However, it is considered as a suitable tool to screen and prioritise the flavouring substances 
according to the need for refined intake data (EFSA, 2004). 
4.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the MSDI approach, which involves the acquisition of data on the 
amounts used in food as flavourings (SCF, 1999). These data are derived from surveys on annual 
production volumes in Europe. These surveys were conducted in 1995 by the International 
Organization of the Flavour Industry (IOFI), in which flavour manufacturers reported the total amount 
of each flavouring substance incorporated into food sold in the EU during the previous year (IOFI, 
1995). The intake approach does not consider the possible natural occurrence in food. 
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Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population7 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999). 
The total annual volume of production of the candidate substances for use as flavouring substances in 
Europe has been reported to be approximately 110 kg (EFFA, 2004b; EFFA, 2011a; EFFA, 2012a; 
Flavour Industry, 2010b). 2-acetylthiophene [FL-no: 15.040], 4,6-dimethyl-2-(1-methylethyl)dihydro-
1,3,5-dithiazine [FL-no: 15.057] and 2-isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine [FL-no: 15.079] 
accounts for 80 kg. For 27 of the 28 supporting substances the annual volume of production is 
approximately 4300 kg in Europe (EFFA, 2012b; EFFA, 2012a; EFFA, 2013a; JECFA, 2003). 
Thiamine hydrochloride [FL-no: 16.027] accounts for 2500 kg and 5-(2-hydroxyethyl)-4-
methylthiazole [FL-no: 15.014] accounts for 1200 kg. There was no reported production in Europe for 
one of the non-Register supporting substances. 
On the basis of the annual volumes of production reported for the candidate substances, the daily per 
capita intakes for each of these flavourings have been estimated (Table 6 and 7).  
The estimated daily per capita intake of 2-isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine [FL-no: 
15.079], from use as a flavouring substance, is 5.7 µg, of 2-acetylthiophene [FL-no: 15.040] is 2.2 µg, 
of 4,6-dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine [FL-no: 15.057] is 1.6 µg and of 4-
butylthiazole [FL-no: 15.118] is 1.3 µg. For the remaining 37 substances, the estimated daily per 
capita intakes are in the range of 0.0012 to 0.85 µg (Tables 6 and 7). 
4.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of the modified Theoretical Added Maximum Daily Intake (mTAMDI) 
values is based on the approach used by SCF up to 1995 (SCF, 1995).  
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the present evaluation of the candidate substances, information on food categories and normal and 
maximum use levels8,9,10 were submitted by the Flavour Industry (EFFA, 2004c; EFFA, 2004d; EFFA, 
2007; Flavour Industry, 2004-5; Flavour Industry, 2010b) for 39 substances. No information on use 
levels have been submitted for [FL-no: 15.057 and 15.079]. The candidate substances are used in 
flavoured food products divided into the food categories outlined in Annex III of the Commission 
Regulation (EC) No 1565/2000, as shown in Table 4. For the present calculation of the mTAMDI, the 
reported normal use levels were used. In case where different use levels were reported for different 
food categories the highest reported normal use level was used. 
Table 4:  Use of Candidate Substances in Various Food Categories for 39 Candidate 
Substances for which Data on Use have been provided 
                                                     
7  EU figure 375 millions. This figure relates to EU population at the time for which production data are available, and is consistent  
 (comparable) with evaluations conducted prior to the enlargement of the EU. No production data are available for the enlarged EU. 
8  ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported usages  
 (EFFA, 2002). 
9  The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived from 12 model  
 flavouring substances (EFFA, 2004a). 
10  The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 “Alcoholic beverages”  
 for substances for which no data have been given for food category 14.2 (EFFA, 2007). 
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Food 
category 
Description Flavourings used* 
01.0 Dairy products, excluding products of category 2 All 
02.0 Fats and oils, and fat emulsions (type water-in-oil) All 
03.0 Edible ices, including sherbet and sorbet All except [FL-no: 
15.135] 
04.1 Processed fruits All 
04.2 Processed vegetables (including mushrooms and fungi, roots and tubers, pulses 
and legumes), and nuts and seeds 
[FL-no: 15.062 and 
15.135] 
05.0 Confectionery All except [FL-no: 
15.062 and 15.135] 
06.0 Cereals and cereal products, including flours and starches from roots and 
tubers, pulses and legumes, excluding bakery 
All 
07.0 Bakery wares All 
08.0 Meat and meat products, including poultry and game All 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  All except [FL-no: 
15.039 and 15.135] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey None 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All except [FL-no: 
15.089] 
13.0 Foodstuffs intended for particular nutritional uses All except [FL-no: 
15.135] 
14.1 Non-alcoholic ("soft") beverages, excluding dairy products All except [FL-no: 
15.135] 
14.2 Alcoholic beverages, including alcohol-free and low-alcoholic counterparts All except [FL-no: 
15.062 and 15.135] 
15.0 Ready-to-eat savouries All except [FL-no: 
15.068] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not 
be placed in categories 1 – 15 
All except [FL-no: 
15.135] 
* No use levels have been submitted for [FL-no: 15.057 and 15.079] 
According to the Flavour Industry the normal use levels are in the range of 0.1 - 2 mg/kg food, and the 
maximum use levels are in the range of 0.2 - 12 mg/kg (EFFA, 2004c; EFFA, 2004d; EFFA, 2007; 
Flavour Industry, 2004-5; Flavour Industry, 2010b) for the 39 of the 41 substances for which use 
levels have been provided (Section 7 and Appendix B).  
The mTAMDI values for the 34 candidate substances from structural class II (see Section 7) range 
from 78 to 220 µg/person/day. For the remaining seven candidate substances from structural class III 
for which data have been provided, the mTAMDI values range from 78 to 250 µg/person/day. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 7 and Appendix B. 
5. Absorption, Distribution, Metabolism and Elimination 
The 41 candidate substances are structurally related to 28 supporting substances evaluated by the 
JECFA in “Sulfur-containing heterocyclic compounds” (JECFA, 2003; JECFA, 2008). The substances 
are divided into subgroups based on the nature of the ring (aromatic (clustered in subgroups A-Ib, A-Ic 
and A-II) vs. non-aromatic (clustered in subgroups B-II and B-IV)) depending on type and number of 
ring heteroatoms (sulphur or sulphur with nitrogen), and the degree of saturation in the non-aromatic 
rings. The assignment of the individual substances to the different subgroups is presented in Table 5 
(The substances previously allocated to subgroup A-Ia, A-III, BI, B-III, B-V and B-VI are no longer 
supported by Industry). The structures of the substances and a description of the characteristic features 
of the subgroups are also given in Table III.1 and the accompanying text in Appendix C. 
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Table 5:  Division of candidate substances into structural subgroups 
Subgroup and common ring structure Register name FL-no 
A Aromatic subgroups  
A-Ia: Thiophene - The substance previously allocated to the group is no longer supported for use as flavouring substance 
in Europe by Industry 
A-Ib: Thiophenes: (with non-thiol-containing ring 
substituents) 
S
R  
2-Acetylthiophene 15.040 
2-Butylthiophene 15.045 
5-Ethylthiophene-2-carbaldehyde 15.074 
2-Hexylthiophene 15.076 
2-Octylthiophene 15.093 
2-Pentylthiophene (Register name: sec-Pentylthiophene)  15.096 
2-Propionylthiophene 15.097 
A-Ic: Thiophenes: (with thiol-containing ring 
substituents) 
S
(R)-SH
 
3-Mercaptothiophene 15.082 
2-Thiophenemethanethiol 15.108 
2-Methyl-3-mercaptothiophene 15.087 
A-II: Thiazoles 
S
N  
2-Methylthiazole 15.089 
2-Ethylthiazole 15.071 
2-Propylthiazole 15.098 
2-Butylthiazole 15.044 
4-Butylthiazole 15.118 
2,4-Dimethylthiazole 15.062 
2,5-Dimethylthiazole 15.063 
5-Ethyl-2-methylthiazole 15.068 
4-Ethyl-2-methylthiazole 15.067 
4-Ethyl-5-methylthiazole 15.069 
2,5-Diethylthiazole 15.052 
5-Methyl-2-pentylthiazole 15.084 
4,5-Dimethyl-2-ethylthiazole 15.058 
2,5-Dimethyl-4-ethylthiazole 15.061 
2,5-Diethyl-4-methylthiazole 15.050 
2,5-Diethyl-4-propylthiazole 15.051 
2-Isobutyl-4-methylthiazole 15.115 
2-Isobutyl-4,5-dimethylthiazole 15.078 
2-Isopropyl-4,5-dimethylthiazole 15.080 
2-Acetyl-4-methylthiazole 15.038 
2-Acetyl-5-methylthiazole 15.039 
2-Acetyl-4-ethylthiazole 15.116 
4-Methyl-2-propionylthiazole 15.085 
A-III: Benzothiazoles - The substance previously allocated to the group is no longer supported for use as flavouring substance 
in Europe by Industry 
B Non-aromatic subgroups: 
B-I : Dihydrothiophenes - The substance previously allocated to the group is no longer supported for use as flavouring 
substance in Europe by Industry 
B-II: Thiazolines 
S
N  
2-Methyl-2-thiazoline 15.086 
2,4-Dimethyl-3-thiazoline 15.060 
2-Isobutyl-3-thiazoline 15.119 
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Table 5:  Division of candidate substances into structural subgroups 
Subgroup and common ring structure Register name FL-no 
B-III: Thiazolidines - The substances previously allocated to the group are no longer supported for use as flavouring 
substances in Europe by Industry 
B-IV: Dithiazines 
NH
S
S
 
Dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine 15.054 
2,4-Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine 15.055 
  
4,6-Dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine 15.057 
2-Isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine 15.079 
Ethyl thialdine 15.135 
B-V: Dihydrothiazines - The substances previously allocated to the group are no longer supported for use as flavouring 
substances in Europe by Industry 
B-VI: Thiadiazine - The substance previously allocated to the group is no longer supported for use as flavouring substance in 
Europe by Industry 
From the few data available on absorption, distribution and elimination of the aromatic candidate 
substances in this FGE, it is anticipated that they may be absorbed and eliminated after 
biotransformation. Some volatile substances may also be eliminated unchanged via exhalation. For the 
non-aromatic substances there are no data available for the candidate or for the supporting substances. 
For the evaluation of the metabolism of the candidate substances, only limited data were available. 
These were confined to a few studies on some thiophene- and thiazole-derivatives (i.e. only directly 
relevant for the evaluation of subgroups-A (A-Ib, A-Ic and A-II)), the aromatic candidate substances. 
Other information was found in several review papers. However, virtually no data were found on the 
metabolism of substances from the B-subgroups possessing non-aromatic ring structures. 
Metabolism of substances in subgroup A-I 
The structurally related thiophene and the ring-substituted thiophenes (A-Ib and A-Ic) may undergo S-
oxidation to give sulphoxides. These primary metabolites may react spontaneously or via glutathione 
transferase with glutathione (GSH), and it is likely that they also exhibit reactivity towards protein 
thiols. The glutathione conjugates may be further metabolised to the corresponding mercapturic acids 
and excreted in the urine. S-oxide intermediates may also be subject to dimerisation via a Diels-Alder 
reaction. In addition, 4,5-epoxide formation has been reported for 2-phenylthiophene, followed by 
subsequent conjugation of the epoxide with glutathione. This may also be anticipated for other ring-
substituted thiophenes. 
Only very limited information was submitted to show whether side-chain oxidation of the ring-
substituted thiophenes could also occur. Based on some studies with a substituted thiazole 
(chlormethiazole) and one (heavily) substituted thiophene (olanzapine), such side-chain reactions may 
be anticipated. For the substances in subgroup A-Ib, metabolites of the side-chain oxidation pathways 
may be expected to be conjugated, e.g. with glucuronic acid. Similar reactions (e.g. omega or omega-1 
oxidations) for ring-substituent chains have been discussed for alkylated pyrazines (EFSA CEF Panel, 
2011a). The thiophene carbaldehyde candidate substance, 5-ethylthiophene-2-carbaldehyde [FL-no: 
15.074], may be expected to be oxidised to the corresponding carboxylic acid. Where applicable, 
conjugation with amino acids (e.g. glycine) or glucuronic acid may also be expected to occur (see 
FGE.13Rev2 (EFSA CEF Panel, 2011b); FGE.14Rev1 (EFSA, 2009a); FGE.17Rev2 (EFSA CEF 
Panel, 2011a)). The acyl-substituted thiophenes [FL-no: 15.040 and 15.097] may be subject to keto-
reduction, possibly followed by conjugation, similar to acetyl derivatives of furans (EFSA CEF Panel, 
2011b) and of pyrazines (EFSA CEF Panel, 2011a). 
The mercapto-group in the ring-substituent of the substances in subgroup A-Ic may undergo S-
methylation to produce the corresponding methyl thioether, with further oxidation to the 
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corresponding sulphoxide and sulphone. They may also react with glutathione or other endogenous 
thiol substances to form mixed disulphides, which may undergo reduction to thiols or oxidative 
desulphuration. Alternatively, they may undergo enzymatic oxygenation resulting in the formation of 
the corresponding sulphinic or sulphonic acids. These metabolites are all expected to be excreted in 
the urine. A more detailed discussion on the metabolism of sulphur compounds can be found in 
FGE.13Rev2 (EFSA CEF Panel, 2011b). 
Metabolism of substances in subgroup A-II 
Thiazoles may be subject to ring S- and N-oxidation. From the various studies with thiazole 
derivatives (A-II), it can be seen that their metabolites may react spontaneously with glutathione, and 
it is likely that they also exhibit reactivity towards biomacromolecules. In addition, for some thiazole 
derivatives, ring C-oxidation may be accompanied by heterocyclic ring cleavage which can result in 
the formation of alpha-diketone and thioamide intermediates. For the latter a relationship with nephro- 
and hepatotoxicity has been established, especially after GSH depletion, but this is a high-dose 
phenomenon. Due to the compound specificity of these reactions, the extent of formation cannot be 
generalised, however, these thioamide intermediates and the S-oxides seem to be quantitatively minor 
metabolites. 
Similarly to the situation with the ring-substituted thiophenes, only very limited information was 
available which could demonstrate whether side-chain oxidation of the ring-substituted thiazoles could 
occur. Based on some studies with a substituted thiazole (chlormethiazole) such side-chain reactions 
may be anticipated. Metabolites of the side-chain oxidation pathways may be expected to be 
conjugated, e.g. with glucuronic acid. Similar reactions (e.g. omega or omega-1 oxidations) for ring-
substituent chains have been discussed for alkylated pyrazines (EFSA CEF Panel, 2011a). The acyl-
substituted thiazoles [FL-no: 15.038, 15.039, 15.085 and 15.116] may be subject to keto-reduction, 
possibly followed by conjugation, similarly to acetyl derivatives of furanes (EFSA CEF Panel, 2011b) 
and pyrazines (EFSA CEF Panel, 2011a). 
Conclusions for the substances in the subgroups A-I to A-II 
From the very limited data available on the aromatic subgroups (A) it is not anticipated that the 
thiophenes (A-I) and thiazoles (A-II) utilise similar metabolic pathways. These sulphur-containing 
heteroaromatic derivatives can be expected to participate in metabolic pathways principally involving 
side-chain C-oxidation, epoxidation of double bonds, oxidation of the ring-S and (for the thiazoles) 
ring-N to yield sulphoxide or sulphones and N-oxides, respectively. The reactive intermediates (e.g. 
epoxides and S-oxides) may be conjugated with glutathione; the glutathione conjugates may be 
excreted directly in the urine or following further biotransformation to the corresponding mercapturic 
acids.  
In the light of the above considerations and as a consequence of the expected reactivity of the thiol 
groups and the possible reactions of the ring side-chains it cannot be anticipated that the substances in 
the aromatic subgroups (A) are metabolised to innocuous substances. The Panel was aware of the 
potential bio-activation of candidate substances with heteroaromatic rings to yield intermediates via 
ring-scission or S/N-oxidation which could be reactive to proteins or DNA. However, taking into 
account available data on structurally related thiazoles and considering the available genotoxicity data 
on thiophenes and thiazoles in the present revision of FGE.21 (FGE.21Rev4) (negative Ames tests and 
a chromosome aberration test), the Panel concluded that there are not sufficient indications to preclude 
the application of the Procedure to the thiophenes and thiazoles (A-I and A-II). 
Metabolism of the substances in subgroups B-II and B-IV 
No specific information was available on the metabolism of the thiazoline- and dithiazine-derivatives 
or related substances for any of these non-aromatic substances in the B-subgroups. It may be 
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speculated that the substances in these groups are metabolised primarily by oxidation of the ring-S, or, 
if applicable, via N-oxidation. In addition, metabolism of the ring substituents is likely to occur. 
The substances exhibiting thioacetal structures could be subject to acid hydrolysis in the stomach, 
similar to oxygen-containing acetals. However, thioacetals are more resistant to hydrolysis than 
oxygen acetals. It is thus to be anticipated that these substances may reach the intestinal lumen intact 
and may also be absorbed as such. 
Conclusions for the substances in the subgroups B-II and B-IV 
Due to the lack of metabolism data it cannot be concluded that the candidate substances in the B-
subgroups will be metabolised to innocuous products. 
A more detailed description of the metabolism is given in Appendix C. 
6. Application of the Procedure for the Safety Evaluation of Flavouring 
Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment, using the mTAMDI approach, is not 
carried out using the Procedure. In these cases the Panel requires more precise data on use and use 
levels. For comparison of the intake estimations based on the MSDI approach and the mTAMDI 
approach, see Section 7. 
For the three thiazolines in subgroup B-II (2-methyl-2-thiazoline [FL-no: 15.086], 2,4-dimethyl-3-
thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 15.119]), the Panel concluded in 
FGE.21Rev3 that in the absence of further genotoxicity data the Procedure could not be applied to 
these substances from subgroup B-II. However, new adequate in vitro genotoxicity studies (gene 
mutation test in bacteria and micronucleus assay in human peripheral blood lymphocytes) on 2-acetyl-
2-thiazoline [FL-no: 15.010], which is considered as a supporting substance for 2-methyl-2-thiazoline 
[FL-no: 15.086] (EFSA CEF Panel, 2012a) have become available. Based on the new data, the Panel 
concluded that 2-methyl-2-thiazoline [FL-no: 15.086] was not of concern with respect to genotoxicity 
and could be evaluated through the Procedure. With respect to genotoxicity,  no studies have become 
available for either the 3-thiazolines in subgroup B-II, 2,4-dimethyl-3-thiazoline [FL-no: 15.060] and 
2-isobutyl-3-thiazoline [FL-no: 15.119], or on the supporting substance (4,5-dimethyl-2-isobutyl-3-
thiazoline [FL-no: 15.032]). These two compounds were therefore not evaluated through the 
Procedure. 
Thus, the Panel concluded that in the absence of further genotoxicity data, the Procedure could not be 
applied to the two substances 2,4-dimethyl-3-thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline 
[FL-no: 15.119]. 
For the safety evaluation of the remaining 39 candidate substances from chemical groups 29 and 30 
the Procedure as outlined in aAppendix A was applied, based on the MSDI approach. The outcome of 
the evaluations of the 41 substances are summarised in Table 7. 
Step 1 
According to the decision tree approach, presented by Cramer et al., 32 of the candidate substances, 
evaluated through the Procedure, are classified into structural class II and seven into structural class III 
(Cramer et al., 1978), see Table 7. 
Step 2 
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None of the 39 candidate substances can be predicted to be metabolised to innocuous products. 
Therefore, the evaluation of all 39 candidate substances, evaluated through the Procedure, proceeds 
via the B-side of the Procedure. 
Step B3 
The 32 candidate substances in structural class II have estimated European daily per capita intakes 
(MSDI) ranging from 0.0012 µg to 2.2 µg (Table 6). These intakes are below the threshold of concern 
of 540 µg/person/day for structural class II substances.  
Similarly, the estimated daily per capita intakes of  the seven candidate substances in structural class 
III, ranging from 0.0073 µg to 5.7 µg (Table 6), are below the threshold of concern for structural class 
III substances of 90 µg/person/day.  
Accordingly, the evaluation of all 39 candidate substances proceeds to step B4. 
Step B4 
Subgroup A-Ib: Thiophenes with non-thiol-containing ring substituents 
No valid toxicity study from which a NOAEL could be established was available for the candidate 
substances or for any relevant supporting substances. Therefore, the Panel concluded that additional 
toxicity data are needed for the seven substituted thiophenes in subgroup A-Ib. Although additional 
toxicity data were provided by Industry on the candidate substance 2-pentylthiophene (Register name: 
sec-pentylthiophene) [FL-no: 15.096] in FGE.21Rev2 (Flavour Industry, 2010a), the Panel considered 
that these data were not valid for the purposes of establishing a relevant NOAEL for the subgroup. 
Accordingly additional toxicity data are still needed for the seven substituted thiophenes [FL-no: 
15.040, 15.045, 15.074, 15.076, 15.093, 15.096 and 15.097] in subgroup A-Ib. 
Subgroup A-Ic: Thiophenes with thiol-containing ring substituents 
A NOAEL of 0.29 mg/kg body weight (bw)/day was reported for the supporting substance 2-thienyl 
disulfide [FL-no: 15.008] in a single-dose level 90-day study in rats. The combined estimated daily 
per capita intake of 0.14 µg for the three candidate substances, 3-mercaptothiophene [FL-no: 15.082], 
2-methyl-3-mercaptothiophene [FL-no: 15.087] and 2-thiophenemethanethiol [FL-no: 15.108], in 
subgroup A-Ic corresponds to 0.0023 µg/kg bw/day at a body weight of 60 kg. Thus, a margin of 
safety of 1.3 x 105 can be calculated. 
On the basis of the application of the Procedure, 3-mercaptothiophene [FL-no: 15.082], 2-methyl-3-
mercaptothiophene [FL-no: 15.087] and 2-thiophenemethanethiol [FL-no: 15.108] are not expected to 
be of safety concern at their estimated levels of intake. 
Subgroup A-II: Thiazoles 
A NOAEL of 25 mg/kg bw/day was reported for the supporting substance 5-acetyl-2,4-
dimethylthiazole [FL-no: 15.011] in a single-dose level 90-day study in rats. The combined estimated 
daily per capita intake of 2.3 µg for the 23 candidate substances in subgroup A-II corresponds to 
0.038 µg/kg bw/day at a body weight of 60 kg. Thus, a margin of safety of 6.6 x 105 can be calculated. 
On the basis of the application of the Procedure, the 23 candidate substances [FL-no: 15.038, 15.039, 
15.044, 15.050, 15.051, 15.052, 15.058, 15.061, 15.062, 15.063, 15.067, 15.068, 15.069, 15.071, 15.078, 15.080, 
15.084, 15.085, 15.089, 15.098, 15.115, 15.116 and 15.118] in subgroup A-II are not expected to be of 
safety concern at their estimated levels of intake. 
Subgroup B-II: Thiazolines 
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No toxicological data were available on 2-methyl-2-thiazoline [FL-no: 15.086]. However, for 2-acetyl-
2-thiazoline [FL-no: 15.010], which is considered a supporting substance for 2-methyl-2-thiazoline 
[FL-no: 15.086], a NOAEL of 1.8 mg/kg bw per day (for [FL-no: 15.010]) from a 90-day rat study. In 
the study, a mixture of flavouring substances (including 2-acetyl-2-thiazoline [FL-no: 15.010] (0.9 %)) 
was examined (Munday and Kirkby, 1971). The estimated daily per capita intake of 0.012 µg (0.0002 
µg/kg bw/day) for [FL-no: 15.086] provides a margin of safety of 9 x 106, in relation to the estimated 
levels of exposure from the use of [FL-no: 15.086] as flavouring substance. The Panel agrees that this 
provides sufficient safety margin and that the flavouring substance 2-acetyl-2-thiazoline [FL-no: 
15.010] can be concluded at step B4 in the Procedure to be of no safety concern. 
Subgroup B-IV: Dithiazines 
There were no toxicological data available on the candidate substances in this subgroup B-IV. 
However, a new adequate 90-day oral toxicity study in rats on the supporting substance 5,6-dihydro-
2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113] from FGE.76Rev1 (EFSA CEF 
Panel, 2013) provides a NOAEL of 9.3 mg/kg bw per day. The combined estimated daily per capita 
intake of approximately 8.2 µg for the candidate substances in subgroup B-IV corresponds to 0.136 
µg/kg bw/day at a body weight of 60 kg. Thus, a margin of safety of 7 x 104 can be calculated. 
On the basis of the application of the Procedure, 2-butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-
dithiazine [FL-no: 15.042], dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine [FL-no: 15.054], 2,4-
dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine [FL-no: 15.055], 4,6-dimethyl-2-(1-
methylethyl)dihydro-1,3,5-dithiazine [FL-no: 15.057], 2-isobutyldihydro-4,6-dimethyl-1,3,5-
dithiazine [FL-no: 15.079] and ethyl thialdine [FL-no: 15.135] are not considered to be of safety 
concern at their estimated levels of intake. However, 2-butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-
dithiazine [FL-no: 15.042] is no longer supported by the Industry (EFSA, 2011). 
Summary of application of the Procedure 
Of the 39 substances evaluated through the Procedure, in total, 32 of the candidate substances are not 
of safety concern at their estimated levels of intake based on the MSDI approach whereas for seven 
candidate substances additional data are required (see Table 7). 
7. Comparison of the Intake Estimations Based on the MSDI Approach and the 
mTAMDI Approach 
The estimated intakes, based on the mTAMDI, for the 32 candidate substances assigned to structural 
class II and evaluated using the Procedure range from 78 to 220 µg/person/day, which is below the 
threshold of concern for structural class II of 540 µg/person/day  
The estimated intakes, based on the mTAMDI, for five candidate substances assigned to structural 
class III and evaluated using the Procedure, range from 78 to 250 µg/person/day. For two of these 
candidate substances (2,4-dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine [FL-no: 15.055], and ethyl 
thialdine [FL-no: 15.135] the mTAMDI values are above the threshold of concern for structural class 
III substances of 90 µg/person/day. For comparison of the MSDI and mTAMDI values, see Table 6. 
For two candidate substances [FL-no: 15.057 and 15.079] assigned to structural class III, no 
information on use levels have been provided. 
Therefore, further information is required for the four substances [FL-no: 15.055, 15.057, 15.079 and 
15.135]. This would include more reliable intake data. On the basis of such additional data, these 
flavouring substances should be reconsidered along the steps of the Procedure. Following this 
procedure additional toxicological data might become necessary. 
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Table 6:  Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(g/capita/day) 
mTAMDI 
(g/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
15.038 2-Acetyl-4-methylthiazole 0.0049 160 Class II 540 
15.039 2-Acetyl-5-methylthiazole 0.0024 160 Class II 540 
15.040 2-Acetylthiophene 2.2 78 Class II 540 
15.044 2-Butylthiazole 0.011 160 Class II 540 
15.045 2-Butylthiophene 0.012 78 Class II 540 
15.050 2,5-Diethyl-4-methylthiazole 0.012 160 Class II 540 
15.051 2,5-Diethyl-4-propylthiazole 0.0012 160 Class II 540 
15.052 2,5-Diethylthiazole 0.015 160 Class II 540 
15.054 Dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine 0.85 160 Class II 540 
15.058 4,5-Dimethyl-2-ethylthiazole 0.015 130 Class II 540 
15.061 2,5-Dimethyl-4-ethylthiazole 0.011 160 Class II 540 
15.062 2,4-Dimethylthiazole 0.61 140 Class II 540 
15.063 2,5-Dimethylthiazole 0.0061 160 Class II 540 
15.067 4-Ethyl-2-methylthiazole 0.0037 160 Class II 540 
15.068 5-Ethyl-2-methylthiazole 0.0061 220 Class II 540 
15.069 4-Ethyl-5-methylthiazole 0.012 160 Class II 540 
15.071 2-Ethylthiazole 0.028 160 Class II 540 
15.074 5-Ethylthiophene-2-carbaldehyde 0.0012 78 Class II 540 
15.076 2-Hexylthiophene 0.12 78 Class II 540 
15.078 2-Isobutyl-4,5-dimethylthiazole 0.12 160 Class II 540 
15.080 2-Isopropyl-4,5-dimethylthiazole 0.012 160 Class II 540 
15.084 5-Methyl-2-pentylthiazole 0.0037 160 Class II 540 
15.085 4-Methyl-2-propionylthiazole 0.0037 160 Class II 540 
15.086 2-Methyl-2-thiazoline 0.012 160 Class II 540 
15.089 2-Methylthiazole 0.018 150 Class II 540 
15.093 2-Octylthiophene 0.012 160 Class II 540 
15.096 sec-Pentylthiophene 0.24 160 Class II 540 
15.097 2-Propionylthiophene 0.12 160 Class II 540 
15.098 2-Propylthiazole 0.085 160 Class II 540 
15.115 2-Isobutyl-4-methylthiazole 0.011 160 Class II 540 
15.116 2-Acetyl-4-ethylthiazole 0.024 160 Class II 540 
15.118 4-Butylthiazole 1.3 160 Class II 540 
15.060 2,4-Dimethyl-3-thiazoline 0.012 160 Class II 540 
15.119 2-Isobutyl-3-thiazoline 0.011 160 Class II 540 
15.055 2,4-Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-
dithiazine 
0.012 160 Class III 90 
15.057 4,6-Dimethyl-2-(1-methylethyl)dihydro-1,3,5-
dithiazine 
1.6  Class III 90 
15.079 2-Isobutyldihydro-4,6-dimethyl-1,3,5-
dithiazine 
5.7  Class III 90 
15.082 3-Mercaptothiophene 0.011 78 Class III 90 
15.087 2-Methyl-3-mercaptothiophene 0.12 78 Class III 90 
15.108 2-Thiophenemethanethiol 0.0073 78 Class III 90 
15.135 Ethyl thialdine 0.012 250 Class III 90 
8. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
Two of the candidate substances [FL-no: 15.060, and 15.119] have not been evaluated through the 
Procedure (see Section 6) and are therefore not considered together with the other 39 candidate 
substances evaluated in FGE.21Rev4 in the combined intake. 
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On the basis of the reported annual production volumes in Europe (EFFA, 2004b; EFFA, 2011a; 
EFFA, 2012a; Flavour Industry, 2010b), the combined estimated daily per capita intakes as 
flavourings of the candidate substances in subgroups, with more than one substance, evaluated through 
the Procedure, from a structural class (SC), are: subgroup A-Ib (seven substances from SC II) 2.7 µg; 
subgroup A-Ic (three substances from SC III) 0.14 µg; subgroup A-II (23 substances from SC II) 2.3 
µg; subgroup B-IV (four substances from SC III) 7.3 µg.  
The 39 candidate substances evaluated through the Procedure, are structurally related to 28 supporting 
substances evaluated by the JECFA at its 59th and 68th JECFA meeting (JECFA, 2002a; JECFA, 
2007). The total combined daily per capita intakes (in Europe) of candidate and supporting substances 
in each of the five subgroups for which supporting substances were available in the same structural 
class (SC)  are: subgroup A-Ib (eight substances from SC II) 3.4 µg; subgroup A-Ic (five substances 
from SC III) 0.21 µg; subgroup A-II (37 substances from SC II) 500 µg; subgroup B-II (two 
substances from SC II) 0.52 µg;  subgroup B-IV (four substances from SC II) 4.5 µg. 
For none of the subgroups do the total combined intakes exceed the thresholds of concern for 
compounds belonging to structural class II of 540 µg/person/day or to structural class III of 90 
µg/person/day. 
9. Toxicity 
9.1. Acute Toxicity 
Data are available for 16 of the 28 supporting substances. The Oral LD50 values in rats or mice ranged 
from 400 - 4800 mg/kg body weight (bw).  
The acute toxicity data are summarised in Table 9.  
9.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Subacute toxicity data were available for the candidate substances 2-pentylthiophene (Register name: 
sec-pentylthiophene) [FL-no: 15.096] and the structurally related thiophene (former [FL-no: 15.106]) 
and thiophene-2-carbaldehyde (former [FL-no: 15.107]) and for 11 supporting substances, of which 
nine are in the Register [FL-no: 15.002, 15.004, 15.005, 15.008, 15.010, 15.011, 15.020, 15.029 and 
15.113] and two are mixtures of structurally related substances (one mixture of 2-isobutyl-4,6-
dimethyldihydro-1,3,5-dithiazine and 4-isobutyl-2,6-dimethyldihydro-1,3,5-dithiazine, and one 
mixture of 2-isopropyl-4,6-dimethyldihydro-1,3,5-dithiazine and 4-isopropyl-2,6-dimethyldihydro-
1,3,5-dithiazine). 
Repeated dose toxicity data are summarised in Table 10. 
Subgroup A-Ib: Thiophenes with non-thiol-containing ring substituents 
In a study conducted in accordance with OECD Test Guideline 407, 2-pentylthiopene (Register name: 
sec-pentylthiophene) [FL-no: 15.096] was administered by gavage to three groups each of five male 
and five female Sprague-Dawley Crl:CD® (SD) IGS BR strain rats, for twenty-eight days, at dose 
levels of 15, 150 or 500 mg/kg bw/day (Dhinsa et al., 2006). A control group of five males and five 
females was dosed with vehicle alone (Arachis oil). Clinical signs during treatment included increased 
salivation in all animals treated with 500 mg/kg bw/day and the majority of animals treated with 150 
mg/kg bw/day. A slight reduction in body weight gain was observed in males only treated with 500 
mg/kg bw/day, while males and females treated with 500 mg/kg bw/day showed an increase in water 
consumption. Haematologic examination revealed haemolytic anaemia in animals treated with 500 and 
150 mg/kg bw/day as evidenced by reductions in haemoglobin, haematocrit and erythrocyte count and 
evidence of reticulocytosis. Clinical chemical determinations on day 28 showed increases in bilirubin 
and alanine aminotransferase for animals of both sexes treated with 500 mg/kg bw/day, with increases 
in bilirubin also noted for both sexes animals treated with 150 mg/kg/day, and in females receiving 15 
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mg/kg bw/day. Absolute and relative liver, kidney and spleen weights were increased in both sexes 
treated with 500 mg/kg bw or 150 mg/kg bw/day per day. At necropsy, animals in these dose groups 
had dark and enlarged spleens. Histopathological examination revealed hepatocellular hypertrophy in 
animals of both sexes treated with 500 and 150 mg/kg bw/day. Histopathological evidence of 
extramedullary haemopoiesis and haemosiderin accumulation in the spleen of animals of both sexes 
treated with 500 and 150 mg/kg bw/day, together with observation of haemosiderin deposits in the 
liver and kidney, were typical of a haemolytic anaemia, as also evidenced by the haematological 
measurements. There was also some evidence of renal damage in males and females treated with 500 
and 150 mg/kg bw/day, as evidenced in occasional animals only by tubular hypertrophy, tubular 
dilatation and tubular basophilia, pyelitis with associated hyperplasia of the renal papillary/pelvic 
epithelium (females only) and globular accumulations of eosinophilic material in the renal tubules 
(males only). Epithelial hyperplasia of the urinary bladder and associated epithelial and subepithelial 
inflammatory cell infiltrates were observed for two females treated with 500 mg/kg bw/day. 
Hypertrophy of the thyroid was reported in animals of both sexes treated with 500 mg/kg bw/day, and 
for males treated with 150 mg/kg bw/day.  
In a follow-up study to evaluate the hepatic effects and the slight increase in bilirubin seen at the 
lowest dose of 15 mg/kg bw/day in the previous study, 2-pentylthiophene was administered by gavage 
to one group of five male and five female Sprague-Dawley Crl:CD® (SD) IGS BR strain rats, for 
twenty-eight consecutive days, at a dose level of 3 mg/kg/day. A control group of five males and five 
females was given vehicle alone (Arachis oil BP). Clinical signs, body weight development and food 
and water consumption monitored during the study revealed no significant differences between test 
and control animals. Haematology and blood chemistry were evaluated for all animals at the end of the 
study and showed no significant changes. There were no treatment-related changes in spleen weights 
for treated animals in comparison to controls. No macroscopic abnormalities were detected at 
necropsy. 
The authors concluded that oral administration of 2-pentylthiophene to rats for a period of up to 
twenty eight days at a dose level of 3 mg/kg bw/day resulted in no toxicologically or haematologically 
significant effects, The NOAEL was considered to be 3 mg/kg bw/day (Marr and Watson, 2007). The 
Panel agrees with this NOAEL. 
The structurally related substance thiophene-2-carbaldehyde [former FL-no: 15.107] (no longer 
supported) was tested in a subacute toxicity test, in which groups of 5 rats (sex not specified) were 
exposed to 0, 95 and 840 mg/kg bw/day for 11 days (Sharp, 1979). No adverse signs or changes in 
behaviour were noted in treated animals. The reported NOAEL was 95 mg/kg bw/day.  
Data are also available from short-term tests on one supporting substance 5-methyl-2-
thiophenecarbaldehyde [FL-no: 15.004] in this subgroup A-Ib, administered to male and female rats 
for 14 days at 10 mg/kg bw/day (Gill and Van Miller, 1987). The substance produced minor body 
weight changes in both sexes and organ weight changes in males only. Finally, based on the available 
data on metabolism, the toxicity of the structurally related thiophene (former [FL-no: 15.106] from 
subgroup AI-a) was not considered sufficiently structurally related to the substituted thiophenes in 
subgroup A-Ib and are therefore not included in this revision of FGE.21. The Panel considered that the 
studies available on the candidate substance in this subgroup AI-b, 2-pentylthiopene (Register name: 
sec-pentylthiophene) [FL-no: 15.096], together with the structurally related thiophene-2-carbaldehyde 
(former FL-no: 15.107]) and the study on the supporting substance (5-methyl-2-
thiophenecarbaldehyde [FL-no: 15.004]) were inadequate for deriving an appropriate NOAEL to be 
used in the Procedure because of the short durations of these studies. According to the practice of the 
Panel, a minimum requirement to provide an adequate NOAEL for flavourings in the Procedure is a 
90-day study. 
Subgroup A-Ic: Thiophenes with thiol-containing ring substituents 
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No toxicity data were available for the three candidate substances in this subgroup [FL-no: 15.082, 
15.087 and 15.108]. The supporting substance 2-thienyl disulfide (2,2’-dithiodithiophene) [FL-no: 
15.008] was tested in a 90-day dietary feeding study in male and female rats at a single dose level of 
0.29 mg/kg bw/day (Morgareidge and Oser, 1970). Body weight changes, food consumption, 
haematological and clinical chemistry parameters were assessed, urinalysis was undertaken and a 
comprehensive range of tissues were examined histopathologically. No changes were detected in any 
of the parameters assessed, and accordingly a NOAEL of 0.29 mg/kg bw/day could be established. 
Subgroup A-II: Thiazoles 
There were no subacute, subchronic or chronic toxicity studies on any of the 23 candidate thiazoles in 
subgroup A-II.  
A 90-day dietary feeding study was carried out on the supporting substance 5-acetyl-2,4-
dimethylthiazole [FL-no: 15.011] in male (23) and female (23) rats, at a single dose level of 
approximately 25 mg/kg bw/day (Shellenberger, 1971). Body weight, food consumption, 
haematological and clinical chemistry parameters were assessed, urinalysis was undertaken and a 
comprehensive range of tissues were examined histopathologically. No changes were detected in any 
of the parameters assessed and accordingly a NOAEL of 25 mg/kg bw/day could be established. 
In a 90-day study on the supporting substance 2-acetylthiazole [FL-no: 15.020], male rats (10/group) 
were fed diets containing 0, 100, 1000 or 10,000 mg/kg test substance, reported to be equivalent to an 
average daily intake of 0, 5, 50 and 500 mg/kg bw/day (Wheldon et al., 1970). The dose level in the 
highest dose group was increased to 20,000 mg/kg at week 6. Test substance-related changes at 10,000 
- 20,000 mg/kg included reduced body weight gain, increased relative liver, adrenal and thyroid 
weights and minimal fatty changes in the liver. The authors reported a NOAEL of 50 mg/kg bw/day. 
However, due to limitations in the study design and reporting, the Panel concluded that this NOAEL 
could not be used in the Procedure. 
Two further 90-day studies were carried out at single dose levels with the supporting substances 2-
methyl-5-methoxythiazole [FL-no: 15.002] and 2,4-dimethyl-5-vinylthiazole [FL-no: 15.005] 
(Posternak et al., 1975). Due to limitations in reporting of experimental details and results, the Panel 
concluded that these studies could not be used to derive a NOAEL to be used in the Procedure. 
Oral intakes of up to 500 mg thiamine/day (8 mg/kg bw/day in a 60 kg individual) have been reported 
to have no adverse effects in humans (SCF, 2001). 
Subgroup B-II: Thiazolines 
There were no toxicological data available for the three candidate substances in this subgroup. The 
supporting substance 2-(sec-butyl)-4,5-dimethyl-3-thiazoline [FL-no: 15.029] was tested in a 90-day 
dietary feeding study in male and female rats (15/sex) at one dose level of approximately 1.2 mg/kg 
bw/day (Babish and Re, 1978). Body weight changes, food consumption, limited haematological and 
clinical chemistry parameters were assessed, urinalysis was undertaken and a comprehensive range of 
tissues were examined histopathologically. No changes were detected in any of the parameters 
assessed and accordingly a NOAEL of 1.2 mg/kg bw/day could be established. 
The supporting substance 2-acetyl-2-thiazoline [FL-no: 15.010] was tested in a 90-day dietary feeding 
study in male and female rats (8/sex). The diet contained 197, 492, 983, 1966, 2949 and 3932 mg/kg 
diet of a mixture of flavouring substances (including 2-acetyl-2-thiazoline [FL-no: 15.010] (0.9 %)) 
(Munday and Kirkby, 1971). The parameters assessed during the study were body weight gain, food 
intake, food utilization, water intake, urine analysis (pH, protein, blood, glucose, refractive index and a 
transaminase activity), serum chemistry (various enzymes, urea-nitrogen, creatinine, various ions, 
several proteins),  organ weights (only heart, liver, spleen, kidneys, brain, testes, adrenals, thyroid and 
pituitary), hematology (packed cell volume, haemoglobin level, white blood cell count and a 
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differential leucocyte count) and histopathology of lung, liver, spleen and kidney. Clearly the 
assessment was much more limited than that of an OECD Guideline 408 study. No changes were 
detected in any of the parameters assessed and accordingly a NOAEL of 1.8 mg/kg bw/day could be 
established for 2-acetyl-2-thazoline [FL-no: 15.010]. 
Subgroup B-IV: Dithiazines 
There were no toxicological data available on the five candidate substances in subgroup B-IV [FL-no:, 
15.054, 15.055 15.057, 15.079 and 15.135].  
Short-term toxicity tests are available on the mixture 2-isobutyl-4,6-dimethyldihydro-1,3,5-dithiazine 
and 4-isobutyl-2,6-dimethyldihydro-1,3,5-dithiazine (Rush, 1989a) and the mixture 2-isopropyl-4,6-
dimethyldihydro-1,3,5-dithiazine and 4-isopropyl-2,6-dimethyldihydro-1,3,5-dithiazine (Rush, 
1989b). The mixtures were incorporated in the diet of Sprague-Dawley rats (5/sex/group) intake of 
approximately 10 mg/kg bw/day over a period of 14 days. No treatment-related effects were seen. The 
Panel considered that these studies were inadequate for deriving a NOAEL to be used in the 
Procedure, because of the short duration of the studies. 
New 14- and 90-day dietary studies in rats were available on the supporting substance 5,6-dihydro-
2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113]. 
A 14-day range-finding dietary study was performed with 5,6-dihydro-2,4,6-tris(2-methylpropyl)-
4H-1,3,5-dithiazine [FL-no: 15.113] (Bauter, 2012). The study was performed in accordance with 
OECD Guideline (TG 407). Groups (3/sex/dietary intake level) of male and female Hsd:SD®  rats 
were fed a diet containing 0 (dietary control), 120, 1,200 and 2,400 mg 5,6-dihydro-2,4,6-tris(2-
methylpropyl)-4H-1,3,5-dithiazine per kg diet. These dietary levels were equal to daily intakes of 
0, 11.3, 111.2 and 217.0 mg/kg bw for males and 0, 11.2, 107.2 and 206.1 mg/kg bw for females. 
Clinical observations were recorded daily and body weights and food consumption observations 
were made on Days 0, 7 and 14. No mortality was observed throughout the course of the study 
and the general condition of the rats was unremarkable. No gross pathology was related to the 
test-substance.  
A 90-day dietary study was performed with 5,6-dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-
dithiazine [FL-no: 15.113] (Bauter, 2013). The study was performed in accordance with OECD 
Guideline (TG 408). Four groups of rats (10/sex/dietary intake level) of male and female CRL 
Sprague-Dawley CD®IGS rats were fed a diet containing 0 (dietary control), 140, 1,050 and 2,100 
mg 5,6-dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine per kg diet. These dietary levels 
were equivalent to daily intakes of 0, 9.3, 67.9 and 131.9 mg/kg bw for males and 0, 11.0, 77.1 and 
153.7 mg/kg bw for females (Bauter, 2013). The animals were observed daily for signs of gross 
toxicity, viability and behavioural changes. Clinical observations of toxicity were performed on 
day 0 and weekly until sacrifice. Animals were weighed on day 0 at the start of the study and 
weekly thereafter. Food consumption and efficiency were measured and calculated weekly. Blood 
chemistry and haematology were performed on blood drawn via sublingual bleed during week 12 
after overnight fast and coagulation assessment was performed prior to necropsy. Urine was 
collected during the 15 hours prior to the blood draw. Prior to initiation of the study and on Day 91 
the eyes of all rats were examined by focal illumination and indirect ophthalmoscopy. At 
termination of the study all animals were sacrificed and subject to full necropsy. The following 
tissues were weighed wet post dissection: adrenals, brain, epididymides, heart, kidneys, liver, ovaries, 
testes, spleen, thymus, uterus with oviducts. Histopathology was performed on a comprehensive 
number of tissues and organs in accordance with the guidelines. 
No mortality was observed in any group throughout the study. There were no toxicologically 
significant or dose-related differences in animals between treatment and control groups in food 
consumption or food efficiency, body weight and body weight gain, and clinical or 
ophthalmological parameters. Only a reduction in food consumption in females at the highest dose 
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was reported to be statistically significant, which, however, was not accompanied with body weight 
changes and was not considered adverse or biologically relevant. No treatment-related differences in 
clinical or gross pathology or in organ weights were observed. Treatment-related microscopic  
findings were reported in the urinary bladder of males and females of the two highest dose groups 
(1050 and 2100 ppm) and involved statistically significant increase in the incidence of minimal to 
slight simple and diffuse hyperplasia of the mucosal epithelium with increased severity in the highest 
dose group. This finding was not correlated to any other clinical or pathological changes.  
The author concluded that under the conditions of the study, the no-observed-adverse-effect level 
(NOAEL) for dietary administration of 5,6-dihydro-2,4,6-tri(2-methylpropyl)-4H-1,3,5-dithiazine 
[FL-no: 15.113] was determined to be 140 m g / k g  d i e t , equivalent to an estimated daily intake 
of 9.3 mg/kg bw/day for males and 11.0 mg/kg bw/day for females, respectively, based on the 
effects noted on the urinary bladder. The Panel agrees to this conclusion and used 9.3 mg kg bw/day 
in the margin of safety assessment of the candidate substances in subgroup B-IV using the Procedure. 
Repeated dose toxicity data are summarised in Table 10. 
9.3. Developmental / Reproductive Toxicity Studies 
No reproductive and developmental toxicity studies have been available for the candidate substances 
or the supporting substances in this revision of FGE.21 (FGE.21Rev4). One study, a combined repeat 
dose/reproductive and developmental toxicity study, in accordance with OECD Guideline 422, has 
been carried out with the structurally related thiophene [former FL-no: 15.106], which is no longer 
supported for use as a flavouring substance in Europe by Industry (EFSA, 2011).  
In the study males were dosed for 42 days and females from 14 days before mating until day 3 of 
lactation (Nagao, 2006). The full report of this study was in Japanese however a summary of the study 
design, results and conclusions to be drawn were available to the Panel in English.  
Groups of Sprague-Dawley rats (13/sex/dose) were dosed thiophene via gavage at dose levels of 0, 25, 
100, or 400 mg/kg bw/day. No adverse effects on copulation, ovulation, or fertility in treatment groups 
were observed when compared with the control groups. However, in each group, abnormal parturition 
was found. Females in the 100 or 400 mg/kg bw/day group, showing evidence of histopathological 
change in the cerebellum, exhibited abnormal lactation. Pups born to the 400 mg/kg bw/day group 
showed reduced birth weights and viability decreased at postnatal day 4. No morphological 
abnormalities associated with the administration of thiophene were found in any pup. With respect to 
effects on reproduction, the NOAEL was suggested by the authors to be 400 mg/kg bw/day for males 
and 25 mg/kg bw/day for females (Nagao, 2006). 
It should be noted however, based on the available data on metabolism, that in the previous versions of 
FGE.21, the toxicity of thiophene was considered separately from the substituted thiophenes in 
subgroup A-Ib (Nagao, 2006). 
 The developmental/reproductive toxicity study is summarised in Table 11. 
9.4. Genotoxicity Studies 
Genotoxicity data were provided for three of the candidate substances, six structurally related 
substances (no longer supported) and four supporting substances. These 13 substances belong to the 
following subgroups: subgroup A-Ia: Thiophene (former [FL-no: 15.106]), subgroup A-Ib: 2-
methylthiophene (former [FL-no: 15.091]), 3-methylthiophene (former [FL-no: 15.092]), 2,5-
dimethylthiophene (former [FL-no: 15.064]), 2-acetylthiophene [FL-no: 15.040], 2-acetyl-3-
methylthiophene (former [FL-no: 15.037]), thiophene-2-carbaldehyde (former [FL-no: 15.107]), 5-
ethylthiophene-2-carbaldehyde [FL-no: 15.074], 5-methylthiophene-2-carbaldehyde [FL-no: 15.004]; 
subgroup A-II: 2,4-dimethylthiazole [FL-no: 15.062], 4,5-dimethylthiazole [FL-no: 15.017], 4-
methylthiazole [FL-no: 15.035] and subgroup B-II: 3-acetyl-2- thiazoline [FL-no: 15.010]. 
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Subgroup A-I: 
The candidate substance 2-acetylthiophene [FL-no: 15.040] produced a negative result in microbial 
tests, using Salmonella typhimurium strains TA98 and TA100, with and without metabolic activation 
and in the SOS chromotest with metabolic activation. 2-Acetylthiophene was reported to be positive 
without metabolic activation in the SOS Escherichia coli chromotest (Mosier et al., 2003). In the same 
study, the structurally related 2-acetyl-3-methylthiophene (former [FL-no: 15.037]), thiophene-2-
carbaldehyde (former [FL-no: 15.107]) and candidate substance 5-ethylthiophene-2-carbaldehyde [FL-
no: 15.074] gave positive results without metabolic activation in the SOS E. coli chromotest. The 
concentrations tested were not reported for any of the substances subjected to the SOS E. coli 
chromotest (Mosier et al., 2003). The Panel considered the endpoint of this test inappropriate for the 
estimation of genotoxic potential. The supporting substance 5-methyl-2-thiophenecarbaldehyde [FL-
no: 15.004] was negative in a microbial mutagenicity assay. The structurally related substances, 
thiophene (former [FL-no: 15.106]), 2-methylthiophene (former [FL-no: 15.091]), 3-methyl-thiophene 
(former [FL-no: 15.092]) and 2,5-dimethylthiophene (former [FL-no: 15.064]) were reported to be 
negative in microbial mutagenicity assays.  
Thiophene (former [FL-no: 15.106]), no longer supported) was tested in accordance with OECD 
guidelines in a bacterial reverse mutation test in strains of S. typhimurium and in strain WP2 uvrA of 
E. coli. strain. No evidence of mutagenic response was reported when strains TA100, TA1535, TA98 
and TA1537 of S. typhimurium were incubated at concentrations of 0, 78.1, 156, 313, 625, 1250, 2500 
and 5000 μg/plate with and without S9 metabolic activation. Toxicity was observed at 1250 μg/plate 
in TA1537, and 2500 μg/plate in strains TA100, TA1535 and TA98 also with and without metabolic 
activation. Toxicity was observed at 5000 μg/plate in WP2 with and without S9 metabolic activation 
(Shibuya, 2006). 
In a chromosomal aberration test, thiophene was tested on Chinese hamster lung cells in accordance 
with Japanese Guidelines. No chromosomal aberrations or polyploidy was reported when incubated 
with concentrations of 0, 210, 420 and 840 μg/mL of thiophene, with and without metabolic activity 
(Tanaka, 2006). 
Subgroup A-II: 
2,4-Dimethylthiazole [FL-no: 15.062] was reported to show a negative result in microbial assays, 
using S. typhimurium, but only in strain TA100 and only in the absence of metabolic activation 
(Voogd et al., 1983). Two supporting substances, 4,5-dimethylthiazole [FL-no: 15.017] and 4-
methylthiazole [FL-no: 15.035] were negative (with and without S9 metabolic activation) in microbial 
mutagenicity assays. 
(Subgroups B-II: 
No genotoxicity information was available for any candidate or supporting substances in this 
subgroup. However, considering the structural similarities between the thiazolines in subgroup B-II 
and the thiazolidines in subgroup B-III, the Panel in FGE.21Rev3 concluded that the thiazolines [FL-
no: 15.060, 15.086 and 15.119] could not be evaluated through the Procedure (see Subgroup B-III in 
FGE.21Rev3 (EFSA CEF Panel, 2012b)). 
However, new in vitro genotoxicity studies (gene mutation test in bacteria and micronucleus assay in 
human peripheral blood lymphocytes) have become available on 2-acetyl-2-thiazoline [FL-no: 
15.010], which is considered to be structurally related to and a supportive substance for the 2-
thiazoline included in this FGE, 2-methyl-2-thiazoline [FL-no: 15.086]. 
Ames test 
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2-Acetyl-2-thiazoline was tested for the induction of gene mutations in Salmonella typhimurium 
strains TA98, TA100, TA1535, TA1537 and TA102 both in the presence and absence of Aroclor 1254 
induced rat liver S9-mix. Two independent experiments were carried out (Mc Garry, 2012).  
In the first experiment, 2-acetyl-2-thiazoline [FL-no: 15.010] was tested in all five strains in the 
absence and presence of S9-mix using the plate incorporation methodology at concentrations of 5, 
15.8, 50, 158.1, 500, 1581 and 5000 μg/plate. No evidence of toxicity was observed. 
In the second experiment, the concentrations of 2-acetyl-2-thiazoline [FL-no: 15.010] used in all 
strains in the absence and presence of S9-mix were 156.3, 312.5, 625.0, 1250, 2500 and 5000 μg/plate 
of 2-acetyl-2-thiazoline, and the pre-incubation method was used for treatments in the presence of S-9. 
No evidence of toxicity was observed. 
It Is concluded that 2-Acetyl-2-thiazoline [FL-no: 15.010] did not induce mutations in five histidine-
requiring strains (TA98, TA100, TA1535, TA1537 and TA102) or S. typhimurium when tested under 
the conditions of the study (Table 12). The study was conducted using GLP and the design complied 
with current recommendations (OECD Guideline 471) and an acceptable top concentration was 
achieved. 
Micronucleus assay 
2-Acetyl-2-thiazoline [FL-no: 15.010] was tested for the induction of chromosome damage and 
potential aneugenic effects in an in vitro micronucleus assay using duplicate human peripheral blood 
lymphocytes prepared from pooled blood from two healthy male volunteers. Treatments were 
performed both in the absence and presence of Aroclor 1254 induced rat liver S9-mix (Watters, 2012).  
Cells were stimulated for 48 hours with phytohaemaglutinin to produce exponentially growing cells. 
A preliminary toxicity range-finding experiment was conducted with S9-mix and 3 hours treatment 
and without S9-mix with 3 and 24 hours treatment. Toxicity was evaluated as the effect of treatment 
on the Replication Index (RI). Twelve concentrations from 4.6 to 1262 μg/mL were tested. The 
concentrations selected for the main experiment were based on toxicity data from this preliminary test. 
In the main experiment, cells were treated for 3 hours, followed by 21 hours recovery (3 + 21 hours), 
with 0, 600, 1000 or 1292 μg/ml of 2-acetyl-2-thiazoline in the absence and presence of S9-mix. The 
levels of toxicity (reduction in RI) at the highest concentration were 15 % and 0 % in the absence and 
presence of S9-mix, respectively. In a parallel assay, cells were treated for 24 hours (24 + 0 hours) 
with 0, 100, 200, 400 or 600 μg/ml of 2-acetyl-2-thiazoline in the absence of S9-mix with no recovery 
period. The highest concentration induced 55 % toxicity. Relevant positive and negative controls were 
included in all experiments. There were 2 replicate cultures per treatment, and 1000 binucleate cells 
per replicate (i.e., 2000 cells per dose) were scored for micronuclei. Thus the study was conducted 
under GLP and the design complies with current recommendations (including OECD Guideline 487), 
No evidence of chromosomal damage or aneuploidy was observed as indicated by the lack of 
increased levels of micronucleated binucleate cells (MNBN) in the presence or absence of rat liver S9-
mix metabolic activation (Table 12). 
In conclusion, 2-acetyl-2-thiazoline [FL-no: 15.010] did not induce micronuclei in male human 
peripheral blood lymphocyte cultures when tested for 3 + 21 hours in the presence of S9-mix for 3 + 
21 hours and 24 + 0 hours in the absence of S9-mix. 
Based on the new studies on the supporting substance 2-acetyl-2-thiazoline [FL-no: 15.010], the Panel 
concluded that 2-methyl-2-thiazoline [FL-no: 15.086] does not give rise to concern with respect to 
genotoxicity and can accordingly be evaluated using the Procedure. 
Subgroup B-IV:  
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No genotoxicity information was available for any candidate or supporting substance in this subgroup.  
Overall conclusion on genotoxicity: 
Based on the new studies on the supporting substance 2-acetyl-2-thiazoline [FL-no: 15.010], the Panel 
concluded that 2-methyl-2-thiazoline [FL-no: 15.086] does not give rise to concern with respect to 
genotoxicity and can accordingly be evaluated using the Procedure. 
For the remaining substances the genotoxicity data are limited and genotoxicity could not be assessed 
adequately for these  substances in the present revision of FGE.21, Revision 4. However, except for 
the two 3-thiazolines, 2,4-dimethyl-3-thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 
15.119], the genotoxicity data available do not preclude the evaluation of the remaining 39 candidate 
substances using the Procedure. 
Data on genotoxicity are summarised in Table 12. 
CONCLUSIONS 
The present revision of FGE.21, FGE.21Rev4, was made owing to additional toxicity data for the 
supporting substance 5,6-dihydro-2,4,6-tris(2-methylpropyl)-4H-1,3,5-dithiazine [FL-no: 15.113], 
which is considered to be structurally related to the candidate substances 2-butyl-4-
methyl(4H)pyrrolidino[1,2d]-1,3,5-dithiazine [FL-no: 15.042], dihydro-2,4,6-triethyl-1,3,5(4H)-
dithiazine [FL-no: 15.054], 2,4-dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine [FL-no: 15.055], 4,6-
dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine [FL-no: 15.057], 2-isobutyldihydro-4,6-dimethyl-
1,3,5-dithiazine [FL-no: 15.079] and ethyl thialdine [FL-no: 15.135], for which additional data were 
required. Further, new in vitro genotoxicity studies have become available on the supporting substance 
2-acetyl-2-thiazoline [FL-no: 15.010], which is considered to be structurally related to and a 
supportive substance for 2-methyl-2-thiazoline [FL-no: 15.086].  
Since the publication of the previous version of FGE.21, FGE.21Rev3, 18 of the original 59 candidate 
substances [FL-no: 15.037, 15.042, 15.043, 15.064, 15.070, 15.072, 15.077, 15.088, 15.090, 15.091, 
15.092, 15.094, 15.099, 15.106, 15.107, 15.114, 15.129 and 15.133], for which additional data were 
required, are no longer supported by Industry for use as flavouring substances in Europe and will 
therefore not be considered any further. Accordingly, FGE.21Rev4 will only deal with 41 candidate 
substances. 
All candidate substances are five- or six-member sulphur-containing heterocyclic compounds, some of 
which also contain nitrogen. They have been divided into two main groups, those with an aromatic 
ring (33 candidate substances) (Group A) and those with a non-aromatic ring structure (eight candidate 
substances) (Group B). All are ring-substituted with one or more of the substituents alkyl, alkenyl, 
aryl, alcohol, keto, thio. For assessment purposes, the following further subdivision of groups (A) and 
(B) has been made: 
Group (A): Aromatic:  
(Subgroup A-Ia: Thiophene. The substance previously allocated to the group is no longer supported 
for use as flavouring substance in Europe by Industry.) 
Subgroup A-Ib: Thiophene derivatives with non-thiol-containing ring substituents.  
Subgroup A-Ic: Thiophene derivatives with thiol-containing ring substituents.  
Subgroup A-II: Thiazole derivatives.  
(Subgroup A-III: Benzothiazoles. The substance previously allocated to the group is no longer 
supported for use as flavouring substance in Europe by Industry.) 
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Group (B): Non aromatic: 
(Subgroup B-I: Dihydrothiophenes. The substance previously allocated to the group is no longer 
supported for use as flavouring substance in Europe by Industry.) 
Subgroup B-II: Thiazolines.  
(Subgroup B-III: Thiazolidines. The substances previously allocated to the group are no longer 
supported for use as flavouring substances in Europe by Industry.) 
Subgroup B-IV: Dithiazine derivatives.  
(Subgroup B-V: Dihydrothiazines. The substances previously allocated to the group are no longer 
supported for use as flavouring substances in Europe by Industry.) 
(Subgroup B-VI: Thiadiazine derivatives. The substance previously allocated to the group is no longer 
supported for use as flavouring substance in Europe by Industry.) 
Two of the 41 candidate substances possess one chiral centre [FL-no: 15.060, and 15.119], two 
substances possess two chiral centres [FL-no: 15.054 and 15.135] and three possess three chiral 
centres [FL-no: 15.055, 15.057 and 15.079]. The stereoisomeric composition has been specified for all 
substances.  
Thirty-four of the candidate substances belong to structural class II and seven belong to structural 
class III. 
Thirty-one of the candidate substances have been reported to occur naturally in a wide range of foods. 
According to the default MSDI approach, the flavouring substances in this FGE.21Rev4 have intakes 
in Europe ranging from 0.0012 to 5.7 µg/capita/day, which are below the thresholds of concern values 
for structural class II (540 µg/person/day) and structural class III (90 µg/person/day) substances. 
On the basis of the reported annual production volumes of the candidate substances as flavourings in 
Europe, the combined estimated daily per capita intakes, per subgroup and structural class range from 
0.14 to 8.0 µg. For none of the subgroups do the total combined intakes exceed the thresholds of 
concern of 540 µg/person/day or  90 µg/person/day for structural class II and III, respectively. 
The candidate substances are structurally related to 28 supporting substances evaluated by the JECFA 
at its 59th and 68th JECFA meetings. The total combined daily per capita intakes (in Europe) of 
candidate and supporting substances evaluated through the Procedure in each of the five subgroups for 
which supporting substances were available are: subgroup A-Ib (eight substances from class II) 3.4 
µg; subgroup A-Ic (five substances from class III) 0.21 µg; subgroup A-II (37 substances from class 
II) 500 µg; subgroup B-II (two substances from SC II) 0.52 µg and subgroup B-IV (four substances 
from SC II) 4.5 µg. 
For none of the subgroups do the combined intakes exceed the thresholds of concern for compounds 
belonging to structural class II of 540 µg/person/day or to structural class III of 90 µg/person/day. 
It is concluded that the genotoxicity data are limited and that genotoxicity could not be assessed 
adequately for the flavouring substances in FGE.21Rev4. However, except for the two  3-thiazolines, 
2,4-dimethyl-3-thiazoline [FL-no: 15.060] and 2-isobutyl-3-thiazoline [FL-no: 15.119], the 
genotoxicity data available do not preclude the evaluation of the remaining 39 candidate substances 
using the Procedure. 
Flavouring Group Evaluation 21, Revision 4 
 
EFSA Journal 2013;11(11):3451 42 
The metabolism data available were insufficient to allow conclusions to be made about the metabolic 
fate of the candidate substances, and accordingly the 39 candidate substances evaluated through the 
Procedure could not be anticipated to be metabolised to innocuous products. However, the Panel 
concluded that the evidence of binding to macromolecules from possible formation of electrophilic 
metabolites, (e.g. by either ring scission or S-oxidation) was not sufficiently strong to preclude the 
application of the Procedure. 
Toxicological data on both candidate and supporting substances were limited and did not include 
information about chronic or reproductive toxicity, with the exception of a combined repeat dose and 
reproduction and developmental toxicity study on the structurally related thiophene [former FL-no: 
15.106]. Valid toxicological data which could provide an adequate margin of safety compared with the 
intakes from use as flavouring substances were only available for the candidate substances from 
subgroup A-Ic (thiophenes with thiol-containing ring substituents), subgroup A-II (thiazoles), 
subgroup B-II (2-thiazolines only) and subgroup B-IV (dithiazines). 
For the remaining candidate substances belonging to the subgroup of thiophenes with non-thiol-
containing ring substituents (A-Ib), the Panel concluded that there were insufficient data available to 
provide margins of safety from their use as flavouring substances and that additional toxicity data are 
needed. 
It is considered that 32 candidate substances evaluated through the Procedure [FL-no: 15.038, 15.039, 
15.044, 15.050, 15.051, 15.052, 15.054, 15.055, 15.057, 15.058, 15.061, 15.062, 15.063, 15.067, 
15.068, 15.069, 15.071, 15.078, 15.079, 15.080, 15.082, 15.084, 15.085, 15.086, 15.087, 15.089, 
15.098, 15.108, 15.115, 15.116, 15.118 and 15.135] are not of safety concern at their estimated levels 
of intake based on the MSDI approach, whereas for seven candidate substances [FL-no: 15.040, 
15.045, 15.074, 15.076, 15.093, 15.096 and 15.097], additional toxicological data are required. 
Furthermore, for two substances [FL-no: 15.060 and 15.119] the Panel concluded that additional 
genotoxicity data are required. 
The estimated intakes, based on the mTAMDI, for the 32 candidate substances assigned to structural 
class II and evaluated using the Procedure, range from 78 to 220 µg/person/day, which is below the 
threshold of concern for structural class II of 540 µg/person/day. The estimated intakes based on the 
mTAMDI of the seven candidate substances assigned to structural class III and evaluated through the 
Procedure ranged from 78 to 250 µg/person/day. For the candidate substances [FL-no:, 15.055 and 
15.135] the estimated intakes are above the threshold of concern for structural class III substances of 
90 µg/person/day. For two candidate substances [FL-no: 15.057 and 15.079], assigned to structural 
class III, no use levels were provided at all. Therefore, more reliable exposure data are required for 
[FL-no: 15.055, 15.057, 15.079, and 15.135]. On the basis of such additional data, these flavouring 
substances should be re-evaluated using the Procedure. Following this procedure, additional 
toxicological data might become necessary. 
In order to determine whether the conclusion for the 39 candidate substances which have been 
evaluated using the Procedure can be applied to the materials of commerce, it is necessary to consider 
the available specifications. Adequate specifications including purity and identity for the materials of 
commerce have been provided for all 39 flavouring substances evaluated through the Procedure.  
Thus, for seven candidate substances [FL-no: 15.040, 15.045, 15.074, 15.076, 15.093, 15.096 and 
15.097] the Panel considered that additional toxicity data are needed. Furthermore, for two substances 
[FL-no: 15.060 and 15.119] the Panel concluded that additional genotoxicity data are required.  
For the remaining 32 flavouring substances [FL-no: 15.038, 15.039, 15.044, 15.050, 15.051, 15.052, 
15.054, 15.055, 15.057, 15.058, 15.061, 15.062, 15.063, 15.067, 15.068, 15.069, 15.071, 15.078, 
15.079, 15.080, 15.082, 15.084, 15.085, 15.086, 15.087, 15.089, 15.098, 15.108, 15.115, 15.116, 
15.118 and 15.135], evaluated using the Procedure, the Panel concluded that they would present no 
safety concern at their estimated levels of intake based on the MSDI approach. 
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SUMMARY OF SAFETY EVALUATION 
Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(g/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound 
[4) or 5)] 
Outcome on the 
material of commerce  
[6), 7), or 8)] 
Evaluation 
remarks 
15.037 
 
2-Acetyl-3-
methylthiophene 
S
O
 
0.18 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
 a) 
15.038 
 
2-Acetyl-4-methylthiazole 
N
S
O
 
0.0049 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.039 
 
2-Acetyl-5-methylthiazole 
N
S
O
 
0.0024 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.040 
 
2-Acetylthiophene 
S
O
 
2.2 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
  
15.043 
 
2-Butyl-5-ethylthiophene S
 
0.0012 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
 a) 
15.044 
 
2-Butylthiazole 
N
S
 
0.011 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.045 
 
2-Butylthiophene S
 
0.012 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
  
15.050 
 
2,5-Diethyl-4-
methylthiazole 
N
S
 
0.012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(g/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound 
[4) or 5)] 
Outcome on the 
material of commerce  
[6), 7), or 8)] 
Evaluation 
remarks 
15.051 
 
2,5-Diethyl-4-
propylthiazole 
N
S
 
0.0012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.052 
 
2,5-Diethylthiazole 
N
S
 
0.015 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.054 
 
Dihydro-2,4,6-triethyl-
1,3,5(4H)-dithiazine 
S NH
S
 
0.85 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.058 
 
4,5-Dimethyl-2-
ethylthiazole 
N
S
 
0.015 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.061 
 
2,5-Dimethyl-4-
ethylthiazole 
N
S
 
0.011 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.062 
 
2,4-Dimethylthiazole 
N
S
 
0.61 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.063 
1758 
2,5-Dimethylthiazole 
N
S
 
0.0061 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.064 
 
2,5-Dimethylthiophene S
 
0.23 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
 b) 
15.067 
 
4-Ethyl-2-methylthiazole 
N
S
 
0.0037 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(g/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound 
[4) or 5)] 
Outcome on the 
material of commerce  
[6), 7), or 8)] 
Evaluation 
remarks 
15.068 
 
5-Ethyl-2-methylthiazole 
N
S
 
0.0061 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.069 
 
4-Ethyl-5-methylthiazole 
N
S
 
0.012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.070 
 
2-Ethyl-5-methylthiophene S
 
0.061 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
 a) 
15.071 
 
2-Ethylthiazole 
N
S
 
0.028 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.072 
 
2-Ethylthiophene S
 
0.0012 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
 b) 
15.074 
 
5-Ethylthiophene-2-
carbaldehyde 
S
O
 
0.0012 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
  
15.076 
1764 
2-Hexylthiophene S
 
0.12 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
  
15.078 
 
2-Isobutyl-4,5-
dimethylthiazole 
N
S
 
0.12 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.080 
 
2-Isopropyl-4,5-
dimethylthiazole 
N
S
 
0.012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.084 
 
5-Methyl-2-pentylthiazole 
N
S
 
0.0037 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(g/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound 
[4) or 5)] 
Outcome on the 
material of commerce  
[6), 7), or 8)] 
Evaluation 
remarks 
15.085 
 
4-Methyl-2-
propionylthiazole 
N
S
O
 
0.0037 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.086 
 
2-Methyl-2-thiazoline 
N
S
 
0.012 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.089 
 
2-Methylthiazole 
N
S
 
0.018 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.091 
 
2-Methylthiophene S
 
0.019 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
 b) 
15.092 
 
3-Methylthiophene S
 
0.12 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
 b) 
15.093 
 
2-Octylthiophene S
 
0.012 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
  
15.094 
 
2-Pentanoylthiophene 
S
O
 
0.0012 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
 a) 
15.096 
2106 
sec-Pentylthiophene S
 
0.24 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
  
15.097 
 
2-Propionylthiophene 
S
O
 
0.12 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
  
15.098 
 
2-Propylthiazole 
N
S
 
0.085 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(g/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound 
[4) or 5)] 
Outcome on the 
material of commerce  
[6), 7), or 8)] 
Evaluation 
remarks 
15.107 
 
Thiophene-2-carbaldehyde 
S
O
 
0.21 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
 a) 
15.115 
 
2-Isobutyl-4-methyl 
thiazole 
N
S
 
0.011 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.116 
 
2-Acetyl-4-ethylthiazole 
N
S
O
 
0.024 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.118 
 
4-Butylthiazole 
N
S
 
1.3 
 
Class II 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.129 
 
Tetrahydro-2,4,6-
trimethyl-1,3,5(2H)-
thiadiazine 
HN NH
S
 
0.61 
 
Class II 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
 a) 
15.060 
 
2,4-Dimethyl-3-thiazoline 
N
S
 
0.012 
 
Class II 
No evaluation 
  c) 
15.090 
 
2-Methylthiazolidine 
NH
S
 
0.024 
 
Class II 
No evaluation 
  d) 
15.099 
 
2-Propylthiazolidine 
NH
S
 
0.012 
 
Class II 
No evaluation 
  d) 
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(g/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound 
[4) or 5)] 
Outcome on the 
material of commerce  
[6), 7), or 8)] 
Evaluation 
remarks 
15.119 
 
2-Isobutyl-3-thiazoline 
N
S
 
0.011 
 
Class II 
No evaluation 
  c) 
15.042 
 
2-Butyl-4-
methyl(4H)pyrrolidino[1,2
d]-1,3,5-dithiazine 
S N
S
 
0.0012 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4)  a) 
15.055 
1763 
2,4-
Dimethyl(4H)pyrrolidino[
1,2e]-1,3,5-dithiazine S N
S  
0.012 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.057 
 
4,6-Dimethyl-2-(1-
methylethyl)dihydro-1,3,5-
dithiazine 
HN
S
S
 
1.6 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.077 
 
4-Hydroxy-2,5-
dimethylthiophen-3(2H)-
one 
S
HO O  
0.12 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
 a) 
15.079 
 
2-Isobutyldihydro-4,6-
dimethyl-1,3,5-dithiazine 
S
N
H
S
 
5.7 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.082 
 
3-Mercaptothiophene S
SH  
0.011 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
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Table 7:  Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(g/capita/day) 
Class 2) 
Evaluation procedure path 
3) 
Outcome on the 
named compound 
[4) or 5)] 
Outcome on the 
material of commerce  
[6), 7), or 8)] 
Evaluation 
remarks 
15.087 
 
2-Methyl-3-
mercaptothiophene 
S
SH  
0.12 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.088 
 
2-Methyl-4,5-
benzothiazole 
N
S
 
0.0085 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
 a) 
15.106 
 
Thiophene S
 
0.12 
 
Class III 
B3: Intake below threshold, 
B4: No adequate NOAEL 
Additional data 
required 
 a) 
15.108 
 
2-Thiophenemethanethiol S
SH
 
0.0073 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.135 
 
Ethyl thialdine 
S
N
H
S
 
0.012 
 
Class III 
B3: Intake below threshold, 
B4: Adequate NOAEL exists 
4) 6)  
15.114 
 
6-Acetyl-2,3-dihydro-1,4-
thiazine 
N
H
S
O
 
0.012 
 
Class III 
No evaluation 
  d) 
15.133 
1766 
5-Acetyl-2,3-dihydro-1,4-
thiazine 
S
N
H
O  
0.61 
 
Class III 
No evaluation 
  d) 
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
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6) No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on 
 stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
a) No longer supported by Industry (EFSA, 2011). 
b) No longer supported by Industry (DG SANCO, 2013). 
c) Concern for genotoxicity. 
d) No longer supported by Industry (EFSA, 2011). Concern for genotoxicity. 
 
 
 
Flavouring Group Evaluation 21, Revision 4 
 
EFSA Journal 2013;11(11):3451 51 
SUPPORTING SUBSTANCES SUMMARY 
Table 8:  Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification 
available 
MSDI (EU) 1) 
(g/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
 2-Isobutyl-4,6-
dimethyldihydro-1,3,5-
dithiazine and 4-isobutyl-
2,6-dimethyldihydro-1,3,5-
dithiazine (mixture) 
S
N
H
S S
N
H
S
(Mixture)
 
3781 
 
101517-87-7 and 
101517-86-6 
1046 
JECFA specification 
(JECFA, 2002b) 
0.1  
No safety concern a) 
Not in EU-
Register 
 2-Isopropyl-4,6-dimethyl 
2,6-dimethyldihydro-1,3,5-
dithiazine and 4-isopropyl-
2,6-dimethyldihydro-1,3,5-
dithiazine (mixture) 
S
N
H
S S
N
H
S
(Mixture)  
3782 
 
104691-41-0 and 
104691-40-9 
1047 
JECFA specification 
(JECFA, 2002b) 
ND  
No safety concern a) 
Not in EU-
Register 
15.001 2-Mercaptothiophene S SH
 
3062 
478 
7774-74-5 
1052 
JECFA specification 
(JECFA, 2002b). 
0.012  
No safety concern 
a) 
Deleted b) 
 
15.002 2-Methyl-5-methoxythiazole 
N
SO
 
3192 
736 
38205-64-0 
1057 
JECFA specification 
(JECFA, 2002b). 
0.012  
No safety concern 
a) 
Category B b) 
 
15.004 5-Methyl-2-thiophenecarbaldehyde 
S
O
 
3209 
2203 
13679-70-4 
1050 
JECFA specification 
(JECFA, 2002b) 
0.73  
No safety concern 
a) 
Deleted b) 
 
15.005 2,4-Dimethyl-5-vinylthiazole 
N
S
 
3145 
2237 
65505-18-2 
1039 
JECFA specification 
(JECFA, 2002b). 
0.012  
No safety concern 
a) 
Category B b) 
 
15.008 2-Thienyl disulfide 
S S
S
S
 
3323 
2333 
6911-51-9 
1053 
JECFA specification 
(JECFA, 2002b). 
0.061  
No safety concern 
a) 
Category B b) 
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Table 8:  Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification 
available 
MSDI (EU) 1) 
(g/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
15.010 2-Acetyl-2-thiazoline 
S
N
O
 
3817 
2335 
29926-41-8 
1759 
 
0.51  
 
Category B b) 
 
15.011 5-Acetyl-2,4-dimethylthiazole 
N
S
O
 
3267 
2336 
38205-60-6 
1055 
JECFA specification 
(JECFA, 2002b). 
0.012  
No safety concern 
a) 
Category B b) 
 
15.013 2-Isobutylthiazole 
N
S
 
3134 
11618 
18640-74-9 
1034 
JECFA specification 
(JECFA, 2002b). 
2.3  
No safety concern 
a) 
 
 
15.014 5-(2-Hydroxyethyl)-4-methylthiazole 
N
SHO
 
3204 
11621 
137-00-8 
1031 
JECFA specification 
(JECFA, 2002b). 
150  
No safety concern 
a) 
 
 
15.015 4-Methyl-5-(2-acetoxyethyl)thiazole 
N
SO
O
 
3205 
11620 
656-53-1 
1054 
JECFA specification 
(JECFA, 2002b). 
8.6  
No safety concern 
a) 
 
 
15.017 4,5-Dimethylthiazole 
N
S
 
3274 
11606 
3581-91-7 
1035 
JECFA specification 
(JECFA, 2002b). 
0.18  
No safety concern 
a) 
 
 
15.018 4-Methyl-5-vinylthiazole 
N
S
 
3313 
11633 
1759-28-0 
1038 
JECFA specification 
(JECFA, 2002b). 
2.1  
No safety concern 
a) 
 
 
15.019 2,4,5-Trimethylthiazole 
N
S
 
3325 
11650 
13623-11-5 
1036 
JECFA specification 
(JECFA, 2002b). 
0.61  
No safety concern 
a) 
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Table 8:  Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification 
available 
MSDI (EU) 1) 
(g/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
15.020 2-Acetylthiazole 
N
S
O
 
3328 
11726 
24295-03-2 
1041 
JECFA specification 
(JECFA, 2002b). 
9.7  
No safety concern 
a) 
 
 
15.021 2-Ethoxythiazole 
N
S O
 
3340 
11611 
15679-19-3 
1056 
JECFA specification 
(JECFA, 2002b). 
0.012  
No safety concern 
a) 
 
 
15.022 2-(sec-Butyl)thiazole 
N
S
 
3372 
11598 
18277-27-5 
1033 
JECFA specification 
(JECFA, 2002b) 
0.024  
No safety concern 
a) 
 
JECFA evaluated 2-(1-
methylpropyl)thiazole 
(CASrn as in Register). 
(R)- or (S)- enantiomer 
not specified by CASrn 
in Register. 
15.026 2-Isopropyl-4-methylthiazole 
N
S
 
3555 
 
15679-13-7 
1037 
JECFA specification 
(JECFA, 2002b). 
19  
No safety concern 
a) 
 
 
15.027 2-Propionylthiazole 
N
S
O
 
3611 
 
43039-98-1 
1042 
JECFA specification 
(JECFA, 2002b). 
0.056  
No safety concern 
a) 
 
 
15.029 2-(sec-Butyl)-4,5-dimethyl-3-
thiazoline 
N
S
 
3619 
 
65894-82-8 
1059 
JECFA specification 
(JECFA, 2002b). 
0.012  
No safety concern 
a) 
 
JECFA evaluated 2-(2-
Butyl)-4,5-dimethyl-3-
thiazoline (CASrn as in 
Register). (R)- or (S)- 
enantiomer not specified 
by CASrn in Register. 
15.030 4,5-Dimethyl-2-ethyl-3-thiazoline 
N
S
 
3620 
 
76788-46-0 
1058 
JECFA specification 
(JECFA, 2002b). 
0.012  
No safety concern 
a) 
 
JECFA evaluated 4,5-
dimethyl-2-ethyl-3-
thiazoline (CASrn as in 
Register). (R)- or (S)- 
enantiomer not specified 
by CASrn in Register. 
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Table 8:  Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification 
available 
MSDI (EU) 1) 
(g/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
15.032 4,5-Dimethyl-2-isobutyl-3-thiazoline 
N
S
 
3621 
 
65894-83-9 
1045 
JECFA specification 
(JECFA, 2002b). 
0.012  
No safety concern 
a) 
 
JECFA evaluated 4,5-
dimethyl-2-isobutyl-3-
thiazoline (CASrn as in 
Register). (R)- or (S)- 
enantiomer not specified 
by CASrn in Register. 
15.033 2-Ethyl 4-methylthiazole 
N
S
 
3680 
11612 
15679-12-6 
1044 
JECFA specification 
(JECFA, 2002b). 
3.2  
No safety concern 
a) 
 
 
15.035 4-Methylthiazole 
N
S
 
3716 
11627 
693-95-8 
1043 
JECFA specification 
(JECFA, 2002b). 
0.097  
No safety concern 
a) 
 
 
15.109 2,4,6-Trimethyldihydro-1,3,5(4H)-
dithiazine 
S NH
S
 
4018 
11649 
638-17-5 
1049 
JECFA specification 
(JECFA, 2002b). 
1.1  
No safety concern 
a) 
 
JECFA evaluated 2,4,6-
trimethyldihydro-4H-
1,3,5-dithiazine (CASrn 
as in Register). (R)- or 
(S)- enantiomer not 
specified by CASrn in 
Register. 
15.113 5,6-Dihydro-2,4,6,tris(2-
methylpropyl)-4H-1,3,5-dithiazine 
S NH
S
 
4017 
 
74595-94-1 
1048 
JECFA specification 
(JECFA, 2002b). 
2.4  
No safety concern 
a) 
 
JECFA evaluated 2,4,6-
triisobutyl-5,6-dihydro-
4H-1,3,5-dithiazine 
(CASrn as in Register). 
(R)- or (S)- enantiomer 
not specified by CASrn 
in Register. 
16.027 Thiamine hydrochloride 
+NH3
N+
S
N
N
HO
2 Cl-  
3322 
10493 
67-03-8 
1030 
JECFA specification 
(JECFA, 2002b). 
300  
No safety concern 
a) 
 
 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
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4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2002a). 
b) (CoE, 1992). 
ND) No intake data reported. 
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TOXICITY DATA 
Table 9:  Acute Toxicity 
Chemical Name [FL-no]*  Species  Sex  Route  LD50 (mg/kg bw)  Reference  
(2-Thienyl disulfide [15.008]) Mouse M, F Gavage 400 (Moran et al., 1980) 
(2-Methyl-5-methoxythiazole [15.002]) Rat NR Oral 1250 (Posternak et al., 1975) 
(2,4-Dimethyl-5-vinylthiazole [15.005]) Mouse M, F Oral 400 – 800 (Moran et al., 1980) 
(5-Acetyl-2,4-dimethylthiazole [15.011]) Mouse M, F Gavage 975 (Moran et al., 1980) 
Mouse M, F Gavage M: 610, F: 620 (Shellenberger, 1971) 
(5-(2-Hydroxyethyl)-4-methylthiazole [15.014]) Mouse M, F Oral 4800 (Calvary and Nelson, 1944) 
(4-Methyl-5-vinylthiazole [15.018]) Mouse M, F Gavage 400 – 800 (Oser, 1970) 
(2-Propionylthiazole [15.027]) Mouse M, F Gavage 2113 (Moran et al., 1980) 
(4-Methylthiazole [15.035]) Mouse F Gavage 0.36 ml/kg (360 mg/kg, based on an 
assumed specific gravity of 1.0 
g/ml) 
(O’Neal et al., 1978) 
Rat M, F Gavage 930 (Mondino, 1981) 
(4,5-Dimethylthiazole [15.017]) Rat M, F Gavage 964.9 (Piccirillo et al., 1982a) 
(2-Ethoxythiazole [15.021]) Rat M, F Gavage 910.9 (Piccirillo et al., 1982b) 
(2-Isopropyl-4-methylthiazole [15.026]) Rat M, F Gavage 0.83 ml/kg (832 mg/kg based on a 
specific gravity of 1.003 g/ml) 
(Griffiths and Babish, 1977) 
(2-Ethyl 4-methylthiazole [15.033]) Rat M, F Oral 540 (Moreno et al., 1981) 
(Thiamine hydrochloride [16.027]) Rat M Gavage 3710 (Sprince et al., 1974) 
(2-(2-Butyl)-4,5-dimethyl-3-thiazoline [15.029]) Mouse M, F Gavage 2827 (Moran et al., 1980) 
(4,5-Dimethyl-2-ethyl-3-thiazoline [15.030]) Mouse M, F Gavage 1265 (Moran et al., 1980) 
(4,5-Dimethyl-2-isobutyl-3-thiazoline [15.032]) Mouse M, F Gavage 3067 (Moran et al., 1980) 
*  Supporting substances are listed in brackets. 
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Table 10:   Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]*  Species; Sex 
No./Group 
Route  Dose levels Duration 
(days)  
NOAEL 
(mg/kg bw/day) 
Reference Comments 
(Thiophene (former [FL-no: 15.106])) Rat;  
M 
5 
Gavage 0, 50, 100, 500, 
1000 mg/kg 
bw/day 
Up to 19 days 100 (O’Donoghue, 1979) Inadequately reported study of short duration.  
Rat; 
M/F 
13 
Gavage 0, 25, 100, 400 
mg/kg bw/day 
42 25 (Nagao, 2006) Only a translated summary report available. 
2-Pentylthiophene [15.096] Rat; 
M/F 
5 
Gavage 0, 15, 150, 500 
mg/kg bw/day 
28 15 (Dhinsa et al., 2006)  
Rat; 
M/F 
5 
Gavage 0, 3 mg/kg 
bw/day 
28 3 (Marr and Watson, 
2007) 
 
(Thiophene-2-carbaldehyde (former 
[FL-no: 15.107])) 
Rat;  
sex not reported 
5 
Diet  0, 0.1, and 1.0 % 
in diet equal to 0, 
95 and 840 
mg/kg bw/day 
11 days 95 (Sharp, 1979) Reduced food consumption and reduced absolute kidney weight. 
Inadequately reported study of short duration. 
(5-Methyl-2-thiophenecarbaldehyde 
[15.004]) 
Rat; 
M, F 
5/sex/group 
Diet  10 mg/kg 
bw/day 
14 days 10 (Gill and Van Miller, 
1987) 
One dose level, GLP study, comprehensively reported, but no 
haematology or clinical chemistry carried out, only a limited number of 
organs examinaed at autopsy and only liver and kidney examined 
histopathologically. Short duration, limited study design. 
(2-Thienyl disulfide [15.008]) Rat;  
M, F 
15/sex 
Diet  0.29 mg/kg bw/ 
day 
90 days 0.29 (Morgareidge and Oser, 
1970) 
Study carried out at a one low dose level. Standard toxicological 
parameters were monitored (body weight, food consumption, 
haematology, urinalysis, histopathology). Parameters assessed were 
reasonably comprehensive. Study considered valid. 
(5-Acetyl-2,4-dimethylthiazole 
[15.011]) 
Rat;  
M, F 
23/sex 
Diet approx. 25 
mg/kg bw/day. 
90 days M: 25.2 
F:24.4 
(Shellenberger, 1971) Old study carried out at a one dose level. Standard toxicological 
parameters were monitored (body weight, food consumption, 
haematology, urinalysis, histopathology). Parameters assessed were 
reasonably comprehensive. Study considered valid. 
(2-Acetylthiazole [15.020]) Rat; M 
5 
Diet  5000 and 10,000 
mg/kg in diet 
equivalent to 250 
and 500 mg/kg 
bw/day 
28 days < 250 (Wheldon et al., 1970) Preliminary dose-range finding study for the 90-day study described 
below, very limited experimental details provided. 
Rat; M 
10 
Diet  0. 100, 1000, 
10,000 mg/kg in 
diet equivalent to 
0.5, 50, 500 
mg/kg bw/day 
90 days 50 (Wheldon et al., 1970) Study considered to be of limited validity, since no clinical chemistry 
was undertaken, limited number of organs weighed, number of organs 
taken for histopathology was limited, and histopathological review 
restricted to 5 animals/sex/group.  
(2-Methyl-5-methoxythiazole [15.002]) Rat; 
M, F 
10-16/sex 
Diet  approx. 9 mg/kg 
bw/day 
90 days M: 8.83 
F: 8.63 
(Posternak et al., 1975) Toxicity data reported as part of a summary publication on a large 
number of flavouring substances. Body weight, food utilisation, 
haematological and histopathology examination undertaken, clinical 
chemistry restricted to blood urea nitrogen, organ weight changes 
restricted to liver and kidney. Due to reporting limitations data quality 
could not be assessed.  
(2,4-Dimethyl-5-vinylthiazole [15.005]) Rat; M, F 
10-16/sex 
Diet  approx. 1 mg/kg 
bw/day 
90 days M: 0.92 
F: 1.0 
(Posternak et al., 1969) Toxicity data reported as part of a summary publication on a large 
number of flavouring substances,. Body weight, food utilisation, 
Flavouring Group Evaluation 21, Revision 4 
 
EFSA Journal 2013;11(11):3451 58 
Table 10:   Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name [FL-no]*  Species; Sex 
No./Group 
Route  Dose levels Duration 
(days)  
NOAEL 
(mg/kg bw/day) 
Reference Comments 
haematological and histopathology examination undertaken, clinical 
chemistry restricted to blood urea nitrogen, organ weight changes 
restricted to liver and kidney. Due to reporting limitations data quality 
could not be assessed.  
(2-Acetyl-2-thiazoline [15.010]) Rat;  
M, F 
8/sex  
Diet  0. 197, 492, 983, 
1966, 2949, 
3932 mg/kg in 
diet equivalent to 
0, 0.09, 0.23,  
0.45, 0.90, 1.4, 
1.8 mg/kg 
bw/day 
13 weeks 1.8 (Munday and Kirkby, 
1971) 
Flavour coctail consisted of 4-hydroxy-5-methyl-2,3-dihydrofuran-3-one 
[FL-no:13.085] (74 %), 2,3-dimethyl-4-hydroxy-2,5-dihydrofuran-5-one 
[FL-no: 10.030] (23 %), 2-acetyl-2-thiazole  [FL-no: 15.020] (1.8 %) 
and 2-acetyl-2-thazoline [FL-no: 15.010] (0.9 %). Dose levels are for 2-
acetyl-2-thiazoline [15.010]. 
 
(2-(2-Butyl)-4,5-dimethyl-3-thiazoline 
[15.029]) 
Rat; 
M, F 
15/sex  
Oral 1.21(M) /1.26 
(F) mg/kg bw/ 
day 
90 days M: 1.21 
F: 1.26 
(Babish and Re, 1978) Old study carried out at a one dose level. Standard toxicological 
parameters were monitored (body weight, food consumption, 
haematology, urinalysis, histopathology). Study considered valid. 
(5,6-Dihydro-2,4,6,tris(2-methylpropyl)-
4H-1,3,5-dithiazine [FL-no: 15.113]) 
Rat 
M, F 
3/6 
Diet 0, 11.3, 111.2, 
217 mg/kg bw 
(M) 
0, 11.2, 107.2, 
206.1 mg/kg bw 
(F) 
14 days >217 (Bauter, 2012) OECD Guideline study (407). 
Rat 
M, F 
3/20 
Diet  0, 9.3, 67.9, 
131.9 mg/kg bw 
(M) 
0, 11.0, 77.1, 
153.7 mg/kg bw 
(F) 
90 days 9.3 (M) 
11.0 (F) 
(Bauter, 2013) OECD Guideline study (408). 
(2-Isobutyl-4,6-dimethyldihydro-1,3,5-
dithiazine and 4-isobutyl-2,6-
dimethyldihydro-1,3,5-dithiazine 
(mixture)) 
Rat,  
M, F 
5/sex 
Oral 10 mg/kg 
bw/day 
14 days M: 11.5 
F: 11.1 
(Rush, 1989a) One dose level study of short duration, no haematological or clinical 
chemistry parametes were examined and histopathological examinations 
were restricted to liver and kidney.  
(2-Isopropyl-4,6-dimethyldihydro-1,3,5-
dithiazine and 4-isopropyl-2,6-
dimethyldihydro-1,3,5-dithiazine 
(mixture)) 
Rat,  
M, F 
5/sex 
Oral 10 mg/kg 
bw/day 
14 days M: 11.8 
F: 11.1 
(Rush, 1989b) One dose level study of short duration, no haematological or clinical 
chemistry parametes were examined and histopathological examinations 
were restricted to liver and kidney.  
*  Supporting substances are listed in brackets. 
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Table 11:  Developmental and reproductive toxicity studies 
Chemical Name  
[FL-no] 
Species/ 
Sex 
No./ group 
Route Dose 
Levels 
Duration NOAEL (mg/kg bw/day), 
Including information of 
possible maternel toxicity 
Reference Comments 
Thiopene  Rats/M, F 
13 
 
Gavage 0, 25, 100, 400 
mg/kg bw/day 
42 days M: 400 mg/kg bw 
F: 25 mg/kg bw 
(Nagao, 2006) Only a translated summary report available. 
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Table 12:  Genotoxicity (In Vitro) 
Chemical Name  
[FL-no]* 
Test System Test Object  Concentration Result  Reference  Comments 
Subgroup A-Ia 
Thiophene 
(former [FL-no: 15.106]) 
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100; 
TA1535; TA1537 
3 µmol/plate (all strains) 
(252 µg/plate) 
Negative 
(S9) 
(Florin et al., 1980) Published non-GLP study. Qualitative screening in a spot-test with three 
strains, quantitative study (4 doses, 0.03, 0.3, 3, 30 µmol/plate) with TA100 
only. Limited report of experimental details and results. Insufficient quality, 
study not considered adequate for the evaluation of mutagenic activity. 
Ames assay  
(preincubation 
method) 
S. typhimurium 
TA97;TA98; TA100; 
TA1535; TA1537 
Up to 10,000 µg/plate  Negative 
(S9)1 
(Zeiger et al., 1987) Non-GLP study roughly in accordance with OECD Guideline 471. The 
study is considered valid. 
Ames assay  
(preincubation 
method) 
S. typhimurium 
TA98; TA100; 
TA102 
0.01 - 1.2 mmol/plate  
(100,968 µg/plate) 
Negative 
(S9) 
(Aeschbacher et al., 
1989) 
Greatest effects are quantified by ”mutation factor,” no numbers are given 
for negative results. Limited quality (only 3 strains used), but otherwise 
acceptable study.  
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(8414 µg/plate) 
Negative 
(S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable study. 
Ames assay S. typhimurium 
TA98, TA100, 
TA1535, TA1537 
0, 78.1, 156, 313, 625, 
1250 µg/plate 
Negative 
(S9) 
(Shibuya, 2006) Valid study according to OECD Test Guidelines and Guidelines for 
screening mutagenicity testing of chemicals (Japan), provided as a 
translation of the original report in Japanese. 
 E. coli WP2 uvrA 0, 78.1, 156, 313, 625, 
1250, 2500, 5000 
µg/plate 
Negative 
(S9) 
  
Chromosomal 
Abberation 
Chinese hamster lung 
cells 
0, 210, 420, 840 µg/ml Negative 
(S9) 
(Tanaka, 2006) Valid study according to Guidelines for screening mutagenicity testing of 
chemicals (Japan), provided as a translation of the original report in 
Japanese. 
Subgroup A-Ib 
2-Methylthiophene 
(former [FL-no: 15.091]) 
Ames assay  
(preincubation 
method) 
S. typhimurium 
TA98; TA100; 
TA102 
0.00001 - 1.0 
mmol/plate  
(98,170 µg/plate) 
Negative 
(S9) 
(Aeschbacher et al., 
1989) 
Greatest effects are quantified by ”mutation factor,” no numbers are given 
for negative results. Limited quality (only 3 strains used), but otherwise 
acceptable study.  
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(9817 µg/plate) 
Negative 
(S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable study. 
3-Methylthiophene 
(former [FL-no: 15.092]) 
Ames assay  
(preincubation 
method) 
S. typhimurium 
TA98; TA100; 
TA102 
0.01 - 1.0 mmol/plate  
(98,170 µg/plate) 
Negative 
(S9) 
(Aeschbacher et al., 
1989) 
Greatest effects are quantified by ”mutation factor,” no numbers are given 
for negative results. Limited quality (only 3 strains used), but otherwise 
acceptable study.  
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(9817 µg/plate) 
Negative 
(S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable study. 
2,5-Dimethylthiophene  
(former [FL-no: 15.064])  
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(11,219 µg/plate) 
Negative 
(S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable study. 
2-Acetylthiophene [15.040] Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(12,618 µg/plate) 
Negative 
(S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable study. 
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Table 12:  Genotoxicity (In Vitro) 
Chemical Name  
[FL-no]* 
Test System Test Object  Concentration Result  Reference  Comments 
 SOS Chromotest E. coli NR  Negative with rat S9,  
positive without rat S9 
(Mosier et al., 2003) Study endpoint inappropriate for the estimation of genotoxic potential. 
2-Acetyl-3-Methylthiophene  
(former [FL-no: 15.037])  
SOS Chromotest E. coli NR Negative with rat S9,  
positive without rat S9 
(Mosier et al., 2003) Study endpoint inappropriate for the estimation of genotoxic potential.  
Thiophene-2-carbaldehyde  
(former [FL-no: 15.107])  
SOS Chromotest E. coli NR Negative with rat S9,  
positive without rat S9 
(Mosier et al., 2003) Study endpoint inappropriate for the estimation of genotoxic potential. 
5-Ethylthiophene-2-
carbaldehyde [15.074] 
SOS Chromotest E. coli NR Negative with rat S9,  
positive without rat S9 
(Mosier et al., 2003) Study endpoint inappropriate for the estimation of genotoxic potential. 
(5-Methyl-2-
thiophenecarbaldehyde 
[15.004]) 
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(12,618 µg/plate) 
Negative 
(S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable study. 
Subgroup A-II 
2,4-Dimethylthiazole [15.062] Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA100 
9.3 and 94 mmol/l top 
agar 
(10,639 µg/ml) 
Negative 
(-S9) 
(Voogd et al., 1983) Insufficient quality (one test strain as well as without metabolic activation 
only).  
(4,5-Dimethylthiazole 
[15.017]) 
Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(11,318 µg/plate) 
Negative 
(S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable study. 
(4-Methylthiazole [15.035]) Ames assay  
(plate incorporation 
method) 
S. typhimurium 
TA98; TA100 
Up to 100 µmol/plate 
(9916 µg/plate) 
Negative 
(S9) 
(Lee et al., 1994) Only two strains used but otherwise acceptable study. 
Subgroup B-II 
(2-Acetyl-2-thiazoline 
[15.010]) 
Reverse mutation S. typhimurium 
TA98, 
TA100, TA1535, 
TA1537 and TA102 
5, 15. 81, 50, 158.1, 500, 
1581 and 5000 μg/plate2 
Negative (Mc Garry, 2012) OECD Guideline study (471). 
   156.3, 312.5, 625.0, 1250, 
2500 and 5000 μg /plate3 
Negative   
 Micronucleus 
induction 
Human peripheral 
blood lymphocytes 
600, 1000 and 1292 μg 
/ml4 
600, 1000 and 1292 μg 
/ml5 
Negative (Watters, 2012) OECD Guideline study (487). 
   100, 200, 400 and 600 μg 
/ml6 
Negative   
*  Supporting substances are listed in brackets. 
NR: Not Reported.  
1 With and without rat and hamster S9 metabolic activation. 
2 With and without metabolic activation. 
3 Assay modified with pre-incubation in the presence of S9. 
4 Without metabolic activation, 3 hours treatment + 21 hours recovery. 
5 With metabolic activation, 3 hours treatment + 21 hours recovery. 
6 Without metabolic activation, 24 hours + 0 hours recovery. 
  
Flavouring Group Evaluation 21, Revision 4 
 
EFSA Journal 2013;11(11):3451 62 
No in vivo mutagenicity/genotoxicity data are available neither for the candidate substance of the present flavouring group evaluation nor for the supporting 
substances evaluated by the JECFA at the 59th and 68th meetings. 
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APPENDIX A: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996; JECFA, 1997; JECFA, 1999). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 µg/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
 can the flavourings be predicted to be metabolised to innocuous products11 (Step 2)?  
 do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
 are the flavourings or their metabolites endogenous12 (Step A4)?  
 does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
11 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997). 
 
12 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products? 
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety  
evaluation 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
 
 
 
 
  Substance would not be    
expected to be of safety concern 
Is the substance or are its metabolites endogenous? 
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4. 
 Yes  No 
 Yes 
 No 
No 
No 
Yes 
No 
Yes 
Yes 
Yes 
 No 
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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APPENDIX B: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000). According to the 
Industry the ”normal use” is defined as the average of reported usages and ”maximum use” is defined 
as the 95th percentile of reported usages (EFFA, 2002). The normal and maximum use levels in 
different food categories have been extrapolated from figures derived from 12 model flavouring 
substances (EFFA, 2004a). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000. 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry for 39 of 41 candidate substances, for 
which use levels have been provided, in the present flavouring group (Table II.1.2).  
Table II.1.2  Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.21Rev (EFFA, 
2004c; EFFA, 2004d, EFFA, 2007; Flavour Industry, 2004-2005; Flavour Industry, 2010b). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
15.038 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.039 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
- 
- 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.040 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.044 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.045 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.050 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.051 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.052 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.054 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.055 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
0,4 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.058 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,1 
0,5 
0,4 
2 
1 
5 
0,2 
1 
15.060 0,4 
2 
0,2 
1 
0,2 
1 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.061 0,4 0,2 0,4 0,3 - 0,4 0,2 0,4 0,1 0,1 - - 0,2 0,4 0,2 0,4 1 0,2 
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Table II.1.2  Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.21Rev (EFFA, 
2004c; EFFA, 2004d, EFFA, 2007; Flavour Industry, 2004-2005; Flavour Industry, 2010b). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
2 1 2 1,5 - 2 1 2 0,4 0,4 - - 1 2 1 2 5 1 
15.062 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
0,4 
2 
- 
- 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
- 
- 
1 
5 
0,2 
1 
15.063 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.067 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.068 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
1 
5 
0,2 
1 
0,4 
2 
- 
- 
0,2 
1 
15.069 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.071 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.074 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.076 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.078 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.080 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.082 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.084 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.085 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.086 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.087 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,1 
0,5 
15.089 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
- 
- 
0,4 
2 
0,2 
1 
0,2 
1 
1 
5 
0,2 
1 
15.093 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.096 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.097 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.098 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.108 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,4 
2 
0,2 
1 
15.115 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.116 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.118 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.119 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
15.135 1,5 
3 
1 
2 
- 
- 
0,5 
1 
0,5 
1 
- 
- 
0,5 
1 
1,5 
3 
1,5 
3 
- 
- 
- 
- 
- 
- 
2 
12 
- 
- 
- 
- 
- 
- 
0,5 
1 
- 
- 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may 
consume the amount of flavourable foods and beverages listed in Table II.2.1. These consumption 
estimates are then multiplied by the reported use levels in the different food categories and summed 
up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed 
per person per day (SCF, 1995). 
Class of product category Intake estimate (g/day) 
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Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed 
per person per day (SCF, 1995). 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as 
outlined in Commission Regulation (EC) No 1565/2000 and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
 Beverages (SCF, 1995) correspond to food category 14.1  
 Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13 and/or 
16 
 Exception a (SCF, 1995) corresponds to food category 5 and 11 
 Exception b (SCF, 1995) corresponds to food category 15  
 Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000) 
 Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000) 
 Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 
(EC, 2000) into the seven SCF food categories used for TAMDI calculation (SCF, 1995). 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
 
The mTAMDI values (see Table II.2.3) are presented for 41 candidate substances in the present 
flavouring group, for which Industry has provided use and use levels (EFFA, 2004c; EFFA, 2004d; 
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EFFA, 2007; Flavour Industry, 2004-5; Flavour Industry, 2010b). The mTAMDI values are only given 
for the highest reported normal use levels (see Table II.2.3). The table also contains the mTAMDI 
values for the 18 substances no longer supported by Industry for use as flavouring substances in 
Europe: [FL-no: 15.037, 15.042, 15.043, 15.064, 15.070, 15.072, 15.077, 15.088, 15.090, 15.091, 
15.092, 15.094, 15.099, 15.106, 15.107, 15.114, 15.129 and 15.133] (DG SANCO, 2013; EFSA, 
2011). 
TableII.2.3 Estimated intakes based on the mTAMDI approach. 
FL-no EU Register name mTAMDI 
(g/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
15.037 2-Acetyl-3-methylthiophene 78 Class II 540 
15.038 2-Acetyl-4-methylthiazole 160 Class II 540 
15.039 2-Acetyl-5-methylthiazole 160 Class II 540 
15.040 2-Acetylthiophene 78 Class II 540 
15.043 2-Butyl-5-ethylthiophene 78 Class II 540 
15.044 2-Butylthiazole 160 Class II 540 
15.045 2-Butylthiophene 78 Class II 540 
15.050 2,5-Diethyl-4-methylthiazole 160 Class II 540 
15.051 2,5-Diethyl-4-propylthiazole 160 Class II 540 
15.052 2,5-Diethylthiazole 160 Class II 540 
15.054 Dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine 160 Class II 540 
15.058 4,5-Dimethyl-2-ethylthiazole 130 Class II 540 
15.061 2,5-Dimethyl-4-ethylthiazole 160 Class II 540 
15.062 2,4-Dimethylthiazole 140 Class II 540 
15.063 2,5-Dimethylthiazole 160 Class II 540 
15.064 2,5-Dimethylthiophene 78 Class II 540 
15.067 4-Ethyl-2-methylthiazole 160 Class II 540 
15.068 5-Ethyl-2-methylthiazole 220 Class II 540 
15.069 4-Ethyl-5-methylthiazole 160 Class II 540 
15.070 2-Ethyl-5-methylthiophene 78 Class II 540 
15.071 2-Ethylthiazole 160 Class II 540 
15.072 2-Ethylthiophene 78 Class II 540 
15.074 5-Ethylthiophene-2-carbaldehyde 78 Class II 540 
15.076 2-Hexylthiophene 78 Class II 540 
15.078 2-Isobutyl-4,5-dimethylthiazole 160 Class II 540 
15.080 2-Isopropyl-4,5-dimethylthiazole 160 Class II 540 
15.084 5-Methyl-2-pentylthiazole 160 Class II 540 
15.085 4-Methyl-2-propionylthiazole 160 Class II 540 
15.086 2-Methyl-2-thiazoline 160 Class II 540 
15.089 2-Methylthiazole 150 Class II 540 
15.091 2-Methylthiophene 78 Class II 540 
15.092 3-Methylthiophene 78 Class II 540 
15.093 2-Octylthiophene 160 Class II 540 
15.094 2-Pentanoylthiophene 160 Class II 540 
15.096 sec-Pentylthiophene 160 Class II 540 
15.097 2-Propionylthiophene 160 Class II 540 
15.098 2-Propylthiazole 160 Class II 540 
15.107 Thiophene-2-carbaldehyde 78 Class II 540 
15.115 2-Isobutyl-4-methyl thiazole 160 Class II 540 
15.116 2-Acetyl-4-ethylthiazole 160 Class II 540 
15.118 4-Butylthiazole 160 Class II 540 
15.129 Tetrahydro-2,4,6-trimethyl-1,3,5(2H)-thiadiazine 4000 Class II 540 
15.060 2,4-Dimethyl-3-thiazoline 160 Class II 540 
15.090 2-Methylthiazolidine 160 Class II 540 
15.099 2-Propylthiazolidine 160 Class II 540 
15.119 2-Isobutyl-3-thiazoline 160 Class II 540 
15.042 2-Butyl-4-methyl(4H)pyrrolidino[1,2d]-1,3,5-dithiazine 160 Class III 90 
15.055 2,4-Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine 160 Class III 90 
15.057 4,6-Dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine  Class III 90 
15.077 4-Hydroxy-2,5-dimethylthiophen-3(2H)-one 78 Class III 90 
15.079 2-Isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine  Class III 90 
15.082 3-Mercaptothiophene 78 Class III 90 
15.087 2-Methyl-3-mercaptothiophene 78 Class III 90 
15.088 2-Methyl-4,5-benzothiazole 160 Class III 90 
15.106 Thiophene 78 Class III 90 
15.108 2-Thiophenemethanethiol 78 Class III 90 
15.135 Ethyl thialdine 250 Class III 90 
15.114 6-Acetyl-2,3-dihydro-1,4-thiazine 160 Class III 90 
15.133 5-Acetyl-2,3-dihydro-1,4-thiazine 4000 Class III 90 
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 APPENDIX C: METABOLISM 
III.1. Introduction 
The candidate substances in this FGE are structurally related to the 28 flavouring substances evaluated 
in “Safety Evaluations of Groups of Related Flavouring Agents: Sulfur-Containing Heterocyclic 
Compounds” (JECFA, 2002a; JECFA, 2003; JECFA, 2007; JECFA, 2008). 
The candidate substances from EU chemical groups 29 and 30 in this FGE include five- and six-
membered sulphur-containing aromatic and non-aromatic heterocycles, which in the previous versions 
of FGE.21 have been arranged into nine subgroups in order to facilitate comparisons of the data sets 
between the groups. This division was done on the basis of degree of aromaticity and according to the 
presence of other heteroatoms (i.e. nitrogen). Subgroup A-I has been further divided into three 
subgroups: A-Ia (thiophene), A-Ib (thiophenes with alkyl, acyl or carbaldehyde ring substituents) and 
A-Ic (thiophenes with thiol-containing ring substituents). So, in total 11 subgroups. In this revision 4, 
FGE.21Rev4, 18 substances are no longer supported by Industrt for the use as flavouring substances 
and have accordingly been deleted from the text unless the information is considered relevant for the 
remaining substances. This means that the following subgroups are no longer considered: A-Ia, A-III, 
B-I, B-III, B-V and B-VI.  
The substances and subgroups are presented in Table III.1: 
Table III.1 Division of candidate and supporting substances into structurally related 
subgroups – supporting substances are listed in brackets 
FL-no EU Register name Structural formula 
A-Ia Thiophene - The substance previously allocated to the group is no longer supported for use as flavouring 
substance in Europe by Industry 
A-Ib Thiophenes (with non-thiol-containing ring substituents) 
(15.004) (5-Methyl-2-thiophenecarbaldehyde) 
S
O
 
15.040 2-Acetylthiophene 
S
O
 
15.045 2-Butylthiophene S
 
15.074 5-Ethylthiophene-2-carbaldehyde 
S
O
 
15.076 2-Hexylthiophene S
 
15.093 2-Octylthiophene S
 
15.096 2-Pentylthiophene (Register name: sec-Pentylthiophene)  S
 
15.097 2-Propionylthiophene 
S
O
 
A-Ic Thiophenes (with thiol-containing ring substituents) 
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Table III.1 Division of candidate and supporting substances into structurally related 
subgroups – supporting substances are listed in brackets 
FL-no EU Register name Structural formula 
(15.001) (2-Mercaptothiophene) S SH
 
(15.008) (2-Thienyl disulfide) 
S S
S
S
 
15.082 3-Mercaptothiophene S
SH  
15.087 2-Methyl-3-mercaptothiophene S
SH  
15.108 2-Thiophenemethanethiol S
SH
 
A-II Thiazoles 
(15.002) (2-Methyl-5-methoxythiazole) 
N
SO
 
(15.005) (2,4-Dimethyl-5-vinylthiazole) 
N
S
 
(15.011) (5-Acetyl-2,4-dimethylthiazole) 
N
S
O
 
(15.013) (2-Isobutylthiazole) 
N
S
 
(15.014) (5-(2-Hydroxyethyl)-4-methylthiazole) 
N
SHO
 
(15.015) (4-Methyl-5-(2-acetoxyethyl)thiazole) 
N
SO
O
 
(15.017) (4,5-Dimethylthiazole) 
N
S
 
(15.018) (4-Methyl-5-vinylthiazole) 
N
S
 
(15.019) (2,4,5-Trimethylthiazole) 
N
S
 
(15.020) (2-Acetylthiazole) 
N
S
O
 
(15.021) (2-Ethoxythiazole) 
N
S O
 
(15.022) (2-(sec-Butyl)thiazole) 
N
S
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Table III.1 Division of candidate and supporting substances into structurally related 
subgroups – supporting substances are listed in brackets 
FL-no EU Register name Structural formula 
(15.026) (2-Isopropyl-4-methylthiazole) 
N
S
 
(15.027) (2-Propionylthiazole) 
N
S
O
 
(15.033) (2-Ethyl 4-methylthiazole) 
N
S
 
(15.035) (4-Methylthiazole) 
N
S
 
15.038 2-Acetyl-4-methylthiazole 
N
S
O
 
15.039 2-Acetyl-5-methylthiazole 
N
S
O
 
15.044 2-Butylthiazole 
N
S
 
15.050 2,5-Diethyl-4-methylthiazole 
N
S
 
15.051 2,5-Diethyl-4-propylthiazole 
N
S
 
15.052 2,5-Diethylthiazole 
N
S
 
15.058 4,5-Dimethyl-2-ethylthiazole 
N
S
 
15.061 2,5-Dimethyl-4-ethylthiazole 
N
S
 
15.062 2,4-Dimethylthiazole 
N
S
 
15.063 2,5-Dimethylthiazole 
N
S
 
15.067 4-Ethyl-2-methylthiazole 
N
S
 
15.068 5-Ethyl-2-methylthiazole 
N
S
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Table III.1 Division of candidate and supporting substances into structurally related 
subgroups – supporting substances are listed in brackets 
FL-no EU Register name Structural formula 
15.069 4-Ethyl-5-methylthiazole 
N
S
 
15.071 2-Ethylthiazole 
N
S
 
15.078 2-Isobutyl-4,5-dimethylthiazole 
N
S
 
15.080 2-Isopropyl-4,5-dimethylthiazole 
N
S
 
15.084 5-Methyl-2-pentylthiazole 
N
S
 
15.085 4-Methyl-2-propionylthiazole 
N
S
O
 
15.089 2-Methylthiazole 
N
S
 
15.098 2-Propylthiazole 
N
S
 
15.115 2-Isobutyl-4-methylthiazole 
N
S
 
15.116 2-Acetyl-4-ethylthiazole 
N
S
O
 
15.118 4-Butylthiazole 
N
S
 
(16.027) (Thiamine hydrochloride) 
H2N
N+
S
N
N
Cl-
HO
 
A-III Benzothiazoles - The substance previously allocated to the group is no longer supported for use as 
flavouring substance in Europe by Industry 
B-I Dihydrothiophenes - The substance previously allocated to the group is no longer supported for use as 
flavouring substance in Europe by Industry 
B-II Thiazolines 
(15.010) 2-Acetyl-2-thiazoline 
S
N
O
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Table III.1 Division of candidate and supporting substances into structurally related 
subgroups – supporting substances are listed in brackets 
FL-no EU Register name Structural formula 
(15.029) (2-(sec-Butyl)-4,5-dimethyl-3-thiazoline) 
N
S
 
(15.030) (4,5-Dimethyl-2-ethyl-3-thiazoline) 
N
S
 
(15.032) (4,5-Dimethyl-2-isobutyl-3-thiazoline) 
N
S
 
15.060 2,4-Dimethyl-3-thiazoline 
N
S
 
15.086 2-Methyl-2-thiazoline 
N
S
 
15.119 2-Isobutyl-3-thiazoline 
N
S
 
B-III Thiazolidines - The substances previously allocated to the group are no longer supported for use as 
flavouring substances in Europe by Industry 
B-IV Dithiazines 
15.054 Dihydro-2,4,6-triethyl-1,3,5(4H)-dithiazine 
S NH
S
 
15.055 2,4-Dimethyl(4H)pyrrolidino[1,2e]-1,3,5-dithiazine 
S N
S
 
15.057 4,6-Dimethyl-2-(1-methylethyl)dihydro-1,3,5-dithiazine 
HN
S
S
 
15.079 2-Isobutyldihydro-4,6-dimethyl-1,3,5-dithiazine 
S
N
H
S
 
(15.109) (2,4,6-Trimethyldihydro-1,3,5(4H)-dithiazine) 
S NH
S
 
(15.113) (5,6-Dihydro-2,4,6,tris(2-methylpropyl)-4H-1,3,5-
dithiazine) 
S NH
S
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Table III.1 Division of candidate and supporting substances into structurally related 
subgroups – supporting substances are listed in brackets 
FL-no EU Register name Structural formula 
15.135 Ethyl thialdine 
S
N
H
S
 
(Not in EU Register) (2-Isobutyl-4,6-dimethyldihydro-1,3,5-dithiazine and 4-
isobutyl-2,6-dimethyldihydro-1,3,5-dithiazine (mixture)) 
S NH
S
S NH
S
(Mixture)
 
(Not in EU Register) (2-Isopropyl-4,6-dimethyl 2,6-dimethyldihydro-1,3,5-
dithiazine and 4-isopropyl-2,6-dimethyldihydro-1,3,5-
dithiazine (mixture)) 
S NH
S
S NH
S
(Mixture)
 
B-V Dihydrothiazines - The substances previously allocated to the group are no longer supported for use as 
flavouring substances in Europe by Industry 
B-VI Thiadiazines - The substance previously allocated to the group is no longer supported for use as flavouring 
substance in Europe by Industry 
 
The following is a description of the characteristic features of the subgroups: 
A Aromatic group: 
Subgroup A-I: Thiophenes (10 candidate substances and three supporting substances): aromatic 
heterocyclic five-membered ring substances with a sulphur atom at ring position 1. This group is 
further divided into subgroups: A-Ib with seven ring-substituted thiophenes which have one or more 
alkyl, acyl or carbaldehyde substituents to the ring and subgroup A-Ic with three ring-substituted 
thiophenes which have a free thiol group in their ring-substituent group (subgroup A-Ia no longer 
supported). 
Subgroup A-II: Thiazoles (23 candidate substances and 17 supporting substances): five-membered 
aromatic heterocycles containing one sulphur and one nitrogen atom in the 1- and 3-ring positions, 
respectively. To this heterocyclic ring one or more alkyl- or acyl- substituents may be attached. 
B Non-aromatic group: 
Subgroup B-II: Thiazolines (three candidate substances and four supporting substances): five-
membered heterocycles containing a sulphur and a nitrogen atom in the 1- and 3-ring positions, 
respectively. In the ring, one double bond is present (in contrast to the thiazoles, which have two 
double bonds (aromatic)).  
Subgroup B-IV: Dithiazines (five candidate substances and four supporting substances): six-
membered non-aromatic heterocycles containing two sulphur atoms, and one nitrogen atom, with 
various ring substituents, including a fused second ring in one of these.  
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III.2. Absorption, Distribution and Elimination 
Only limited data were submitted for the evaluation of the absorption, distribution and elimination of 
the candidate flavouring substances in this group. The absorption and elimination were studied for 
thiophene13 [former FL-no: 15.106]. Data were also submitted for a few more or less related 
substances. Because the information is so fragmentary, it is not useful to present it (sub)group-wise. In 
addition, some of the studies are related to oral exposure and some others to parenteral dosing, and the 
relevance of the latter may be limited.  
Single doses of 33 mg/kg bw [2,5-14C]-thiophene were administered to mice via oral and rectal 
intubation. At 48 hours after the oral gavage dose, 78 % of the radioactivity was found in the urine, 
while 5 % was found in both faeces and expired air. At 24 hours after the rectal dose, 43 % was found 
in the urine, but 40 % was found in the expired air. The difference in the elimination pattern after oral 
vs. rectal administration was attributed to an extensive first-pass effect after the oral dose. Also, the 
oral dose resulted in 10 times higher levels of radioactivity in the liver as compared to the rectal dose. 
With thin-layer chromatography two urinary metabolites were observed. However, none of these 
metabolites and none of the radioactivity in tissues or excreta were further identified (Chanal et al., 
1974). 
Female rats (200 - 250 g) and rabbits (2 - 3 kg) were administered thiophene as single oral gavage 
doses of 60 mg and 450 mg, respectively. Urine was collected over a 24 hours period following 
dosing. Table III.2 provides a summary of the quantitative determinations of metabolites in this study. 
Table III.2 Summary of excretion of metabolites of thiophene in rabbits and rats 
Metabolites Rabbit (N = 6) Rat (N = 3) 
(Pre)-mercapturic acids in urine 38 (32 – 49) 40 (36 – 45) 
Free thiophene expired Not determined 32 (29 – 35) 
Free thiophene in faeces Not determined 0.48 (0.25 – 0.68) 
Tabulated data are percentage of administered dose (%) 
Other urinary metabolites, in particular conjugates of 2-hydroxy- or 3-hydroxythiophene, but no acid-
hydrolysable products of thiophene or free thiophene were found (Bray et al., 1971). 
When male Sprague-Dawley rats were injected intraperitoneally with a 200 mg/kg bw dose of tritiated 
(at C2 and C5 positions) thiophene in corn oil, approximately 31 % of the radioactivity was excreted 
between 0 and 15 hours, while 4 % of the radioactivity was excreted between 15 and 50 hours. More 
than 94 % of the urinary radioactivity was accounted for by a single metabolite, the 2-mercapturic acid 
derivative of 1,4-dihydrothiophene-S-oxide (Dansette et al., 1992). 
In rats, a single subcutaneous dose of 35S-thiophene was rapidly absorbed into the blood stream. 
Thiophene produced a peak blood concentration within 30 minutes and peak levels in the brain within 
three hours. Radioactivity was excreted in the urine at 61.1 % of the dose within 34 hours and 74.4 % 
of the dose within three days (Bikbulatov and Nigmatullina, 1976; O’Donoghue, 2000). 
Non-candidate substances: 
                                                     
13 Structural formula:  
S
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In two male Sprague-Dawley rats, approximately 20 % of the radioactivity of an intraperitoneal 
injection of 30 mg/kg bw of the 3-aroylthiophene (tienilic acid isomer 1)14 (14C at the keto position) is 
recovered in the urine within 24 hours. Approximately 15 % of urinary radioactivity could be 
accounted for as a mixture of two diastereoisomers of the mercapturic acid conjugate of the 3-aroyl-
4,5-dihydrothiophene. The study was designed to identify these two metabolites. The rest of the 
urinary radioactivity was identified as parent substance (ca. 17 % of the dose) and an unidentified 
metabolite (ca. 1 % of the dose), presumably a derivative of one or both of the already identified 
mercapturates (Valadon et al., 1996). 
When the benzothiazole derivative fostedil15 was administered to dogs via intravenous infusion or 
orally as solution, suspension or as encapsulated substance, mean relative bioavailabilities for the 
parent substance after oral dosing could be calculated to be 71, 64 or 42 %, respectively. The 
substance was cleared from the plasma with a terminal half-life of 6 - 9 hours and based on high 
biliary excretion, enterohepatic circulation has been suggested. When the substance was administered 
with a radiolabel (no further details) 80 % of the radioactivity was found in the faeces (Thomas, 1984; 
Thomas and Bopp, 1984).  
In a previous FGE.24Rev1 (EFSA, 2008), data on the absorption and elimination of indole16 have been 
discussed. As this substance bears some resemblance to the benzothiazoles in subgroup A-III, these 
data are also briefly mentioned here. After oral dosing of 2-14C-indole to rats, 62 - 82 % of the 
administered radioactivity was excreted via urine or expired air within 48 - 72 hours post-dosing. 
The substances in subgroup B-IV (the dithiazines with FL-no: 15.054, 15.055, 15.057, 15.079 and 
15.135) may be regarded as cyclic thioacetals, which could be subject to acid hydrolysis in the 
stomach, similar to oxygen-containing acetals. However, thioacetals are more resistant to hydrolysis 
than oxygen acetals. In addition, chances of hydrolysis would be reduced even more by their cyclic 
character (Smith and March, 2001; EFSA CEF Panel, 2011c). It is thus anticipated that these 
substances may be expected to reach the intestinal lumen intact and may also be absorbed as such. 
III.3. Metabolism 
In the sections below, the metabolism data available have been presented according to the division into 
subgroups of the candidate flavouring substances in this FGE. 
                                                     
14 Structure of 3-aroylthiophene (isomer of tienilic acid (2-aroylthiophene)): 
S
O
Cl Cl
O
O
OH
 
15 Structure of fostedil: 
S
N P
O
O
O CH2CH3
H3CH2C  
 
16 Strucure of indole: 
N
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 Aromatic candidate substances 
Subgroup A-Ib thiophenes with non-thiol-containing ring substituents 
(Candidate substances [FL-no: 15.040, 15.045, 15.074, 15.076, 15.093, 15.096 and 15.097]) 
Data on the structurally related substance thiophene 
Thiophene (former [15.106]) was administered to female rats (200 - 250 g) and rabbits (2 - 3 kg) as 
single oral gavage doses of 60 mg and 450 mg, respectively. Urine was collected over a 24 hours 
period following dosing. The predominant metabolites excreted in the urine were a mercapturic acid 
and a premercapturic acid, which according to the study authors could result from the conjugation of 
glutathione with an intermediate 2,3-thiophene-epoxide. 2-Thienylmercapturic acid was excreted in 
relatively small quantities and 3-hydroxy-2,3-dihydro-2-thienyl-mercapturic acid was the major 
metabolite excreted in urine. The metabolites were identified by IR spectroscopy, GLC and MS 
techniques and further by characteristic chemical reactions of thiophene derivatives (desulphuration 
following treatment of the premercapturic acid with Raney nickel resulting in the formation of 2-
butanol) (Bray et al., 1971). 
More recently, male Wistar rats (190 - 400 g) were injected intraperitoneally with 0.2 mmol (= ~ 17 
mg) thiophene in peanut oil, and mercapturic acids were not found to be important thioethers (i.e. 
comprising not more than about 1 % of the dose) excreted in the urine (Hickman et al., 1992), contrary 
to the results of Bray et al (Bray et al., 1971). It is noted that 2-thienyl mercapturic acid was also 
identified as a less important metabolite by Bray et al. (1971) and that the two studies differ in route of 
administration. The oral route of administration (Bray et al., 1971) results in higher metabolic 
conversion as compared to the intraperitoneal one (Hickman et al., 1992). In addition, identification of 
thioethers by Hickman et al. (1992) was only done by reaction with Ellman’s reagent following 
extraction and hydrolysis of the urine samples. No attempts were made to identify any other thiophene 
metabolite in urine samples. 
When male Sprague-Dawley rats were injected (intraperitoneal) with 200 mg/kg bw [2,5-3H]-labelled 
thiophene, more than 94 % of the urinary radioactivity was accounted for by the 2-mercapturic acid 
derivative of 2,5-dihydrothiophene-S-oxide, as identified by NMR, IR and Mass spectroscopical 
techniques. A small second peak in the HPLC diagram of the urine radioactivity was also observed, 
but this peak was not further studied. The authors concluded that its formation occurred by S-oxidation 
yielding the very reactive thiophene sulphoxide, which undergoes Michael-type addition of 
glutathione at the 2-position. In subsequent reactions, the glutathione moiety of this metabolite is 
converted into an N-acetyl cysteine group. The final metabolite is subsequently excreted via urine, and 
may be converted spontaneously into 2-thienyl-mercapturic acid (Dansette et al., 1992). The authors 
considered the formation of the epoxide intermediate, as suggested by Bray et al. (1971), highly 
unlikely.  
Based on subsequent studies with chemically defined reaction mixtures and with microsomal 
incubations, the formation of the 2,5-dihydrothiophene-S-oxide was further substantiated by the 
formation of two diastereoisomeric thiophene S-oxide dimers (3a,4,7,7a-tetrahydro-4,7epithio-
benzo[b]thiophene 1,8 dioxide) one of which (the 1-syn,-8-syn,endo-isomer) was suggested having 
been observed in the in vivo studies by Dansette et al (ca. 10 % of urinary radioactivity, comprising 2 
% of the oral dose in the above study; the unidentified second peak (see above)). The formation of the 
dimers may result from a Diels−Alder reaction. Thus, the metabolic fate for the thiophene S-oxide in 
vivo involves predominantly reaction with nucleophiles such as glutathione (catalysed by glutathione 
S-transferase) leading eventually to mercapturate derivatives that are excreted in the urine, or to a 
lesser extent it involves dimerization and the resulting dimer is also excreted via the urine (Treiber et 
al., 1997). 
Non-candidate substances: 
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In two male Sprague-Dawley rats injected i.p. with the 3-aroylthiophene tienilic acid isomer 1 (see 
above), 15 % of urinary radioactivity (~ 2 % of the dose) could be accounted for as a mixture of two 
diastereoisomers of the mercapturic acid conjugate of 3-aroyl-4,5-dihydrothiophene. In the ultimate 
urinary metabolite, the N-acetylcysteine residue (mercapturate) is found in the 4-position of the 
thiophene ring. This residue may be introduced at that position after initial Michael-type addition of 
glutathione to the primary thiophene sulphoxide metabolite (see Figure III.1) at the ring position 2 (i.e. 
the C next to the S atom) and several rearrangements, including ring opening / closing and reaction 
with second GSH molecules. Results of in vitro experiments with rat liver microsomes indicate that 
the thiophene sulphoxide is a reactive intermediate in the conversion of the 3-aroylthiophene to the 
dihydromercapturic acid metabolite (Valadon et al., 1996). 
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Figure III.1. Proposed metabolism of 3-alkylthiophenes 
 
Oxidation of 2-phenylthiophene by rat liver microsomes, in the presence of NADPH and glutathione 
(GSH) involves two initial reactions, resulting in three subsequent types of metabolites. The first 
reaction involves S-oxidation to yield 2-phenylthiopene S-oxide that then dimerizes by Diels–Alder 
type reaction of the S-oxide. Alternatively, the S-oxide alternatively may form a glutathione adduct via 
a 1,4-Michaël-type addition of glutathione to the C5 position of 2-phenylthiopene S-oxide. The second 
metabolic reaction involves formation of a 2-phenylthiophene-4,5-epoxide which may be subject to 
subsequent conjugation with glutathione at C4 of the thiophene ring. Subsequent dehydration of the 
resulting hydroxyl-glutathione conjugate yields the corresponding glutathione conjugate of 
phenylthiopene which is excreted mainly as the 2-mercapturic derivative. Oxidation of 2-
phenylthiophene by recombinant, human cytochrome P450 1A1, in the presence of NADPH and 
glutathione, also led to these metabolites. These results provide the evidence that cytochrome P450 
(1A1) may catalyze the oxidation of thiophene compounds with the simultaneous formation of two 
reactive intermediates, a thiophene-S-oxide and a thiophene epoxide (Dansette et al., 2005). 
The addition of alkyl substituents can result in a significant change in metabolism. Biotransformation 
of a thiophene derivative was studied in six male healthy volunteers after administration of a single 
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oral dose of 12.5 mg olanzapine17. Mean radiocarbon recovery was 87 %, with 30 % appearing in the 
feces and 57 % excreted in the urine. In addition to other metabolites, the methyl substituent on the 
thiophene ring underwent oxidation to the corresponding 2-hydroxymethyl and 2-carboxylic acid 
derivatives. There was no evidence for glutathione conjugation of the thiophene S-oxide or 
epoxidation of the thiophene ring double bond for alkyl-substituted thiophenes (Kassahun et al., 1997). 
However, the total recovery and identification of metabolites in urine or faeces was far from complete 
and some metabolites may have been missed in the analysis. In addition, reactions alternative to S-
oxidation (e.g. N-oxidation or n-glucuronidation) may greatly reduce the relevance of the S-oxidation 
in this substance as compared to more simple alkyl-substituted thiophenes. 
Subgroup A-Ic: Thiophenes with a thiol group in the ring substituent 
Candidate substances [FL-no: 15.082, 15.087 and 15.108] 
There is no specific information on any of the candidate substances in this subgroup, or on stucturally 
related thiophene derivatives. It may be anticipated that some of the metabolic conversions described 
above for subgroups A-Ia and A-Ib may also apply to this subgroup.  
In addition, the mercapto-group (thiol) in the ring-substituent chain may undergo S-methylation to 
produce the corresponding methyl thioether or sulphide, with further oxidation to the corresponding 
sulphoxide and sulphone. They may also react with glutathione or other endogenous thiol substances 
to form mixed disulphides, which may undergo reduction to thiols, or oxidative desulphuration. 
Alternatively, they may undergo enzymatic oxygenation resulting in the formation of the 
corresponding sulphinic or sulphonic acid. All these metabolites are expected to be excreted in the 
urine. A more detailed discussion on the metabolism of sulphur compounds may be found in another 
EFSA-CEF opinion on other sulphur-containing flavouring substances (EFSA CEF Panel, 2011b). 
Additional considerations for the candidate substances in Subgroup A-I 
No information was submitted that would indicate whether side-chain oxidation of the alkyl-
substituted thiophenes or keto-reduction of the acyl-substituted thiophenes could occur. Such reactions 
may be anticipated (e.g. omega or omega-1 oxidations). Similar reactions have been discussed for 
alkylated pyrazines and furans in previous opinions (EFSA CEF Panel, 2011a; EFSA CEF Panel, 
2011b). In addition, the aldehyde candidate substance, 5-ethylthiophene-2-carbaldehyde [FL-no: 
15.074] may be expected to be oxidised to the corresponding carboxylic acid. Where applicable, 
conjugation with amino acids (e.g. glycine) or glucuronic acid may also be expected to occur (EFSA, 
2009a; EFSA CEF Panel, 2011a; EFSA CEF Panel, 2011b).  
Rance (1989) has indicated that unsubstituted thiophene may be subject to S-oxidation and ring 
substitution. It was stated that S-oxides of thiophene are highly reactive. In this review several studies 
have been quoted with C2 substituted thiophene derivatives (in particular the pharmaceuticals tienilic 
acid, morantel and pyrantel) for which it was demonstrated that ring C5 hydroxylation of these 
substituted thiophenes may occur to a considerable extent. In contrast C2, C5 disubstituted thiophenes 
are less susceptible to ring hydroxylation (Rance, 1989). 
Subgroup A-II: Thiazoles  
                                                     
17 
HN
N
S
N
N
*
*
 Structure of Olanzapine; the radioactive carbons are indicated with *.  
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Candidate substances [FL-no: 15.038, 15.039, 15.044, 15.050, 15.051, 15.052, 15.058, 15.061, 
15.062, 15.063, 15.067, 15.068, 15.069, 15.071, 15.078, 15.080, 15.084, 15.085, 15.089, 15.098, 
15.115, 15.116 and 15.118] 
No specific information was available for any of the candidate substances in this subgroup. 
Non-candidate substances: 
Thiamine hydrochloride [FL-no: 16.027] and 5-(2-hydroxyethyl)-4-methylthiazole [FL-no: 15.014] 
Thiamine (see Figure III.2) is excreted in the urine as unchanged substance but also in the form of 25 – 
30 metabolites, some of which still contain the pyrimidine moiety, while other metabolites are 
generated as a result of molecular cleavage.  
In fish and micro-organisms, breakdown of thiamine is catalysed by two enzymes, namely thiaminase 
I and thiaminase II (Tietz, 1986; Tanphaichitr, 1976). Based on comparative studies in which rodents 
were given thiamine intravenously or orally, it has been demonstrated that in the gastrointestinal tract 
thiamine may already be split into a pyrimidine and a thiazole derivative, namely 5-(2-hydroxyethyl)-
4-methylthiazole, which together with its oxidation product (4-methylthiazole-5-acetic acid) and 
parent thiamine have been identified in urine. The fate of the pyrimidine derivative will not be further 
discussed. The relevance of the intraintestinal cleavage may be different among various animal species 
(Informatics Inc., 1974). 
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Figure III.2. Metabolism of thiamine and 5-(2-hydroxyethyl)-4-methylthiazole 
Chlormethiazole 
The therapeutic agent chlormethiazole (5-(2-chloroethyl)-4-methylthiazole; see Figure III.3), is an 
alkyl- and chloroalkyl-substituted thiazole derivative that is metabolised by C-oxidation of the alkyl- 
and chloroalkyl-substituents and by S- and N-oxidation. In male humans, a 1000 mg oral dose of 
chlormethiazole is metabolised via side-chain C-oxidation of the ethyl C1-position to yield 5-(1-
hydroxyethyl)-4-methylthiazole, 5-acetyl-4-methylthiazole, 5-(1-hydroxy-2-chloroethyl)-4-
methylthiazole, 4,5-dimethylthiazole and 4-methylthiazole-5-acetic acid, which is the major C-
oxidation urinary metabolite (see Figure III.3). Presumably, the 5-methyl derivative is formed via 
decarboxylation of the 5-acetic acid metabolite. Additionally, oxidation of the methyl group at C4 in 
5-(2-hydroxyethyl)-4-methylthiazole yields 5-(2-hydroxyethyl)-4-thiazolecarboxylic acid lactone. 
Separate ring sulphoxide and ring N-oxide products were not identified, but a combined ring S- and N-
oxide of a side-chain oxidised metabolite was also eliminated in the 12-hour urine of volunteers. This 
was the first reported example of a sulphoxidation of a thiazole sulphur and simultaneous oxidation of 
two different heteroatoms in the same heteroaromatic ring in vivo (Offen et al., 1985). 
Moore et al. (1975) reported the excretion of urinary metabolites of chlormethiazole after oral 
administration of this anticonvulsant drug (in the form of its unstable chlormethiazole 
ethanedisulphonate derivative) to humans. The substance was given in capsules to three volunteers 
(sex unknown) in an amount of 768 mg. Urinary samples were collected for up to 36 hours post-
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dosing and processed for the identification and quantification of metabolites by GS-MS techniques. 
Results of urinalysis were compared to results obtained with reference substances. After oral 
administration about 16 % of the dose could be identified in the 36 hours urine as 4 substances parent 
chlormethiaziole (< 0.01 % of the dose), 5-acetyl-4-methylthiazole, 5-(1-hydroxyethyl)-4-
methylthiazole (free and as unspecified conjugate) and 4-methylthiazole-5-acetic acid (> 75 % of all 
metabolites identified). 5-(2-Hydroxyethyl)-4-methylthiazole was only found in trace amounts. In 
addition, a metabolite was tentatively identified as 4-methyl-5-thiazole-acetaldehyde. The authors 
noted that at that time 80 % of the dose was still unaccounted for, which might indicate extensive 
metabolism of the substance in humans (Moore et al., 1975). 
It has also been reported that chlormethiazole undergoes nucleophilic attack at C2, which would 
ultimately result in ring opening. The exact mechanism for the formation of ring opening products has 
not been well-described/identified, but the products are nonetheless found in human urine. It was 
suggested that N-oxidation followed by glutathione conjugation and subsequent glutathione break-
down would yield the 2-thiomethyl derivative of chlormethiazole, whereas hydroxide ion attack would 
yield 2,4-pentanedione-3-thiol and thiodiacetic acid. The authors suggest that the N-oxidation would 
make the C2 prone to nucleophilic attack (Grupe and Spiteller, 1982; Pal and Spiteller, 1982). 
According to data from Grupe & Spiteller (1982), urinary excretion of thiodiacetic acid may comprise 
up to about 5 % of the dose of chlormethiazole in humans. For the other metabolites (see Figure III.3) 
no quantitative data were provided. 
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Figure III.3. Metabolism of Chlormethiazole. 
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Herbertz et al. (1973) studied the metabolism of (2-14C)-chlormethiazole-ethane disulphonate in 
isolated recycling-perfused rat liver. After 2 hours, 35 % of the system's radioactivity was found in the 
bile, which activity was associated with a polar metabolite, not observed in previous in vivo studies in 
urine. This metabolite was identified as a mixture of N,4-dimethyl-thiazole-5-acetic acid, 2-hydroxy-
N,4-dimethyl-thiazole-5-acetic acid and the glycine conjugate of the latter. Other substances in the 
perfusate were chlormethiazole, 2-hydroxy-4-methyl-5-(2-chloroethyl)thiazole, 4-methyl-5-(2-
hydroxyethyl)thiazole, 4-methylthiazole-5-acetic acid, 2-hydroxy-4-methyl-thiazole-5-acetic acid and 
its glycine conjugate (Herbertz et al., 1973).  
In vivo, the urine was identified as the primary route of elimination (70 % of the dose within 3 hours in 
a study by Allgen et al., 1963 (cited by Herbertz et al., 1973), with no formation of N-methylated 
products. Hence, it was speculated that in vivo enterohepatic recycling of chlormethiazole-metabolites 
would occur, in particular of the N-methylated substances, which would be de-methylated in the 
gastro-intestinal tract and subsequently be excreted via the kidneys. It was noted that the difference 
between the observations in vivo and the perfused system may have occurred because of the build-up 
of (secondary) metabolite levels in the (closed) perfused system (Herbertz et al., 1973). 
Mizutani et al. (1993) investigated the relationship between the toxicological profile of several 
thiazole derivatives and the toxicity of the ring cleavage products in particular the thioamide 
metabolites (see Figure III.4). The various thiazoles were nephrotoxic in vivo in GSH-depleted mice, 
which toxicity decreased upon substitution at the ring 4 and 5 carbons. The larger the substituents, the 
less nephrotoxic the substances appeared to be. In addition to being nephrotoxic, some of the thiazoles 
studied were also hepatotoxic. In the ring C4- and C5-substituted derivatives, ring substitution at the 2 
position carbon (the one between the S and the N atom) markedly reduced the nephrotoxicity, but the 
hepatotoxicity was maintained, except when the substituted was a hydroxyl group (e.g. 2-hydroxy-4-
methylthiazole). It was also demonstrated that thioformamide was both nephrotoxic and hepatotoxic, 
but only in GSH-depleted animals. Thioamides from ring C2 substituted thiazoles appeared to be only 
hepatotoxic, both after GSH-depletion and in normal animals, although in the normal animals the 
hepatotoxicity was less pronounced (Mizutani et al., 1993). Thus, the toxicity appears to be associated 
with GSH-depletion, which is a high-dose phenomenon. 
In additional studies, again with mice, administration of another non-flavouring thiazole derivative 
with known hepatotoxic and nephrotoxic properties, 4-t-butyl-2-methylthiazole, at a dose of 312 
mg/kg bw by gavage, resulted in limited ring C-oxidation. Only 0.25 % of the administered dose was 
recovered as a ring fragmentation product (3,3-dimethyl-2-oxobutanal; an alpha-dicarbonyl 
metabolite) in the urine within 24 hours. In addition, a thioamide metabolite (thioacetamide) was 
found; but this was not quantified. Other metabolites were not studied. Based on the structure of the 
dicarbonyl fragment, it was postulated that the 4,5-double bond of the thiazole ring undergoes 
epoxidation followed by hydrolysis to yield 4,5-diol. The diol then undergoes hydrolytic cleavage to 
yield the corresponding carbonyl derivatives and thioacetamide. Similar, thiazole ring opening has 
also been observed with thiabendazole (= 2-(thiazol-4-yl)benzimidazole) and with 2-(p-
methoxyphenyl)-4-methylthiazole (Mizutani et al., 1994). 
Additional information for candidate substances in Subgroup A-II 
In an extensive review on the metabolism of heterocyclic substances, Rance (1989) indicated that 
several alternative metabolic pathways are available to thiazoles. One involves oxidation of S to form 
the corresponding sulphoxide and sulphone. Electrophilic attack at the ring N (resulting in 
quaternisation, e.g. N-methylation) is stated to be even more preferential than S-oxidation. The C2 
carbon atom is electron deficient and substituents at this position are reactive and subject to 
nucleophilic displacement, in particular if the ring N is quaternised. Another pathway involves 
electrophilic attack at ring carbons, preferably C5. The C5 hydroxythiazoles exist as two tautomeric 
forms. C5-hydroxylation, however, is quantitatively unimportant because thiazoles do not readily 
undergo electrophilic substitution reactions (Rance, 1989). 
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Alkyl- and acyl-substituted thiazole derivatives can be metabolised via side-chain oxidation and ring 
S- and N-oxidation (Dalvie et al., 2002). The major metabolites are readily excreted in the urine either 
free or as glutathione conjugates. In addition, it may be expected that the presence of alkyl- and acyl-
substituents at the thiazole ring increases the number of metabolic options. It has also been 
demonstrated that to a very small extent ring C-oxidation may be followed by ring cleavage to yield 
alpha-diketone and thioamide fragments (see Figure III.4). The acyl-substituted thiazoles [FL-no: 
15.038, 15.039, 15.085 and 15.116] may also be expected to undergo keto-reduction, possibly 
followed by conjugation, similar to acetyl derivatives of furane (EFSA CEF Panel, 2011b) and 
pyrazine (EFSA CEF Panel, 2011a). However, there is very limited information to evaluate the extent 
of metabolism of ring substituent groups, and it is also very difficult, based on the information 
available, to assess how the presence of ring substituents and their positions at the ring might influence 
the metabolism of the ring itself. 
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Figure III.4. Metabolism of 4-alkylthiazols 
 Non-aromatic candidate substances 
Subgroups B-II, and B-IV: Thiazoline and Dithiazine derivatives 
Candidate substances [FL-no: 15.060, 15.086 and 15.119] (thiazolines from subgroup B-II), 
Candidate substances [FL-no: 15.054, 15.055, 15.057, 15.079 and 15.135] (dithiazines from subgroup 
B-IV) 
No specific information was available to evaluate the metabolism of any of the candidate substances 
mentioned in these twosubgroups (B-II and B-IV). 
It may be speculated that the substances in these chemical groups which contain a partially or 
completely reduced thiazole or dithiazine, are metabolised primarily by oxidation of the ring S or via 
N-oxidation, similar to the aromatic thiazole compounds. In addition, metabolism of the ring 
substituents is likely to occur. 
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III.4. Summary on metabolism 
The candidate substances in this FGE are structurally related to 28 flavouring substances evaluated by 
the JECFA in “Safety Evaluations of Groups of Related Flavouring Agents: Sulfur-Containing 
Heterocyclic Compounds”. The candidate and 28 supporting substances in this group were originally 
subdivided into 11 subgroups based on the nature of the ring (aromatic (clustered in subgroups A-I to 
A-III) vs. non-aromatic (clustered in subgroups B-I to B-VI)), type and number of ring heteroatoms 
(sulphur or sulphur with nitrogen), and the degree of saturation in the non-aromatic rings. In this 
revision, FGE.21Rev4, the use as flavouring are no longer supported by Industry for 18 candidate 
substances, reducing the number of subgroups to five. 
For the evaluation of the metabolism of the candidate substances in this group, only very limited data 
were available. These were confined to a few references on thiophene, and some thiophene- and 
thiazole-derivatives (i.e. only directly relevant for the evaluation of subgroups-A the aromatic 
candidate substances). Other information was found in several review papers. Virtually no data were 
found on the possible metabolism of the non-aromatic ring structures in the B-subgroups.  
 A-subgroups (substances with aromatic ring structures) 
Very few data are available on absorption, distribution and excretion. Some of the studies are related 
to oral exposure and some others to parenteral dosing, and the relevance of the latter may be limited. 
In mice, a thiazolobenzimidazole derivative was rapidly absorbed after oral dosing, S-oxidised, and 
eliminated from plasma. The structurally related substance thiophene has been shown to be absorbed 
rapidly from the gastro-intestinal tract and eliminated via urine as metabolites, or via the lungs. Also 
the thiazole derivative fostedil is absorbed from the gastro-intestinal tract (42 - 71 % of the dose), 
metabolised and eliminated with a plasma half-life of about 6 - 9 hours in dogs. Hence, from the data 
on absorption and elimination that are available for the aromatic candidate substances in this FGE, it 
may be speculated that most of them will be fairly well absorbed and eliminated after 
biotransformation. Some volatile substances may also be eliminated via the lungs. For the non-
aromatic candidate substances no information is available. 
From the available metabolism data, it may be anticipated that the sulphur- and nitrogen containing 
heterocyclic and heteroaromatic derivatives participate in metabolic pathways, principally involving 
side-chain C-oxidation, oxidation of the ring S and ring N to yield sulphoxide or sulphones and N-
oxides, respectively. Sulphoxide metabolites may conjugate with glutathione or may undergo 
dimerisation via a Diels-Adler reaction. For substituted thiophenes also epoxidation of the double 
bonds has been reported, which may also be followed by glutathione conjugation and mercapturic acid 
formation. As far as studied, ring C-oxidation may to a very minor extent be accompanied by 
heterocyclic ring cleavage, which for thiazoles could result in the formation of reactive thioamide 
intermediates.  
Additional alkyl and acyl substituents in the thiazole ring may increase the alternative metabolic 
pathways available to thiazole derivatives as was demonstrated for chlormethiazole. Alkyl- and acyl-
substituted thiazole derivatives are primarily metabolised via side-chain oxidation and ring S- and N-
oxidation. The major metabolites are readily excreted in the urine either free or as glutathione 
conjugates. Metabolites of the side-chain oxidation pathways may be expected to be conjugated e.g. to 
glucuronic acid. To a very small extent ring C-oxidation may be followed by ring cleavage to yield 
alpha-diketone and thioamide fragments. The acyl-substituted thiazoles [FL-no: 15.038, 15.039, 
15.085 and 15.116] may also be expected to undergo keto-reduction, possibly followed by 
conjugation, similar to acyl derivatives of furanes (EFSA CEF Panel, 2011b) and pyrazines (EFSA 
CEF Panel, 2011a).  
The structurally related thiophene and the ring-substituted thiophenes (subgroups A-Ib and A-Ic) 
undergo S-oxidation and glutathione conjugation. Also from some studies with thiazole derivatives, it 
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can be seen that their metabolites may react spontaneously with glutathione, and it is likely that they 
have also reactivity towards protein thiols, which may result in toxicity. E.g. for the thiazole-ring 
cleavage products (thioamide-intermediates) a relationship with nephrotoxicity and hepatotoxicity has 
been established, especially after GSH depletion, even though this is only a very minor metabolite. 
Limited information was submitted that indicates that side-chain oxidation of the alkyl- or acyl-
substituted thiophenes (subgroups A-Ib and A-Ic) or thiazoles (subgroup A-II) may also occur. Such 
reactions may be anticipated (e.g. omega or omega-1 oxidations). Similar reactions have been 
discussed for alkylated pyrazines (EFSA CEF Panel, 2011a). In addition the candidate substance with 
aldehyde group [FL-no: 15.074] may be expected to be oxidised to the corresponding carboxylic acid. 
Where applicable, conjugation with amino acids (e.g. glycine) or glucuronic acid may also be 
expected to occur (EFSA, 2005; EFSA CEF Panel, 2011a; Scheline, 1968).  
Based on the MSDI exposure estimates (see Table 6, Section 7, of the main text) it seems reasonable 
to assume that saturation of the metabolic pathways for the candidate substances in this FGE is 
unlikely, given these low levels of exposure to the candidate substances from their use as flavouring 
substances.  
Overall there is insufficient quantitative information to evaluate the extent of metabolism of ring 
substituent groups, and it is also very difficult, based on the data available, to assess how the presence 
of ring substituents and their positions at the ring influences metabolism of the rings itself, for any of 
the subgroups within this FGE. With respect to sulphydryl reactivity in thiophenes (subgroup A-Ic), 
this property was a reason to consider such substances, e.g. FGE.13, as not being metabolised through 
pathways leading to innocuous metabolites. In concordance with this and based on the information 
presented above, it is concluded that for all candidate flavouring substances in A-subgroups of the 
present FGE, it cannot be anticipated that they are metabolised to innocuous metabolites. 
 B-subgroups (substances with non-aromatic ringstructures) 
No specific information was available on the metabolism of the thiazoline- or dithiazine-derivatives or 
of related substances for any of the (non-aromatic) substances in the B-subgroups. It may be 
speculated that the substances in these chemical groups are metabolised primarily by oxidation of the 
ring S or, if applicable, via  N-oxidation, similar to the aromatic thiazole and thiophene compounds. In 
addition, metabolism of the ring substituents is likely to occur. Due to the lack of metabolism data on 
the substances in the B-subgroups, it cannot be concluded that the candidate flavouring substances in 
the respective B-subgroups will be metabolised to innocuous products. 
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ABBREVIATIONS 
ADI  Acceptable Daily Intake 
BW  Body Weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC  European Commission 
EFFA  European Flavour and Fragrance Association 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
GLP  Good Laboratory Practice 
GSH  Glutathione 
FLAVIS (FL) Flavour Information System (database) 
HPLC  High-performance liquid chromatography 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IP   Intraparenteral 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
MNBN  Micronucleated binucleate cells 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
MTS  Minimum Toxicity Screen 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NADPH Nicotinamide Adenine Dinucleotide Phosphate, reduced form 
NMR  Nuclear magnetic resonance 
No  Number 
NOAEL No Observed Adverse Effect Level 
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NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
RI   Replication Index 
SC  Structural class 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation  
 
